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The concept that the environment in which we live can have detrimental effects on our
health has existed for centuries. Obvious examples of substances that can cause human dis-
eases include infectious agents, poisons, chemicals and other noxious agents, drugs, and physi-
cal stimuli such as bright lights and loud sounds. Some less obvious agents can include
allergens, nontangible agents such as colorless, odorless gases and aerosolized toxins. In recent
decades, humans have developed various new materials and compounds. Additionally, we are
now producing known compounds, and even naturally occurring substances, in vastly increased
amounts. Many of these substances are generally believed to threaten the health of our environ-
ment. However, there is also a considerable amount of hype and exaggeration regarding some
of these agents (e.g., mold) that is unsubstantiated. This article extensively reviews the data on
a large number of airborne-related illnesses and attempted to place scientific reality in the
context of clinical medicine.
Index Entries
Sick Building Syndrome; volatile organic compounds; formaldehyde; phthalates; organo-
phosphate pesticides; organochlorines; particulate matter; biologicals.
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The Sick Building Syndrome
One of the most widespread consequences
of the use of new materials in ever more air-
tight buildings may be the so-called Sick Build-
ing Syndrome (SBS). SBS is a rather poorly
defined term referring to a set of nonspecific
skin, mucous membrane, neurological, respi-
ratory, and generalized symptoms experienced
by people working in nonindustrial environ-
ments in the absence of a known causative
agent; these symptoms diminish or disappear
during absences from these work environ-
ments (1). These introductory comments are
made with the understanding that the vast
majority of so-called SBS outbreaks have been
shown secondary to discrimination bias, sec-
ondary gain, or both. However, a number of
important illnesses can occur in very air-tight
buildings. With the recognition that such non-
specific symptoms are reported in almost all
office buildings, as well as in schools, libraries,
hospitals, homes for the elderly, and apart-
ments, they are increasingly referred to as
building-related symptoms. This can be some-
what misleading because the terms “building-
related symptoms” and “building-related ill-
ness” used to be reserved for symptoms with
identified causes (2,3). Confusion can be avoided
by distinguishing between nonspecific and spe-
cific building-related illnesses. For the sake of
simplicity, we use the term SBS for the nonspe-
cific symptomatology experienced by occu-
pants of nonindustrial buildings.
SBS symptoms most commonly are general
or neurophysiological or affect mucous mem-
branes, the upper and lower respiratory sys-
tems, or the skin. General symptoms include
headache, dizziness, nausea, mental fatigue,
difficulty in concentrating, and lethargy. Upper
respiratory and mucosal symptoms consist of
dry, itchy, sore, burning, or otherwise irritated
eyes, nose, sinuses, or throat, whereas lower
respiratory symptoms include cough, wheeze,
difficulty breathing, and chest tightness. Red,
dry, or itchy skin is the most common derma-
tological manifestation.
The prevalence of SBS symptoms ranges
between a few percent and 50 to 60%; addition-
ally, with 70% of US workers (or approx 89
million people) employed in nonindustrial
indoor settings (4), SBS constitutes one of the
most common environmental health issues (3).
The economic impact of productivity losses
and health care costs has been estimated to
amount to $50 to $100 billion, of which $5 to
$75 billion is potentially preventable by using
the appropriate measures (4).
Appropriate measures are currently diffi-
cult to identify because the underlying causes
of SBS remain largely unknown, although it
has been associated with a large variety of fac-
tors, including building, work environment,
demographic, and personal characteristics (see
Table 1). One finding has clearly emerged from
the studies analyzing these associations: the
etiology of SBS is multifactorial, arising from
complex interactions between chemical, physi-
cal, biological, and psychosocial factors (3).
The ventilation rate is one of the work envi-
ronment features most consistently associated
with SBS symptoms. From a review of the lit-
erature, a multidisciplinary group of European
scientists concluded that ventilation rate was
strongly associated with perceived air quality,
SBS symptoms, and various other health out-
comes such as inflammation, infections, asthma,
allergy, and short-term sick leave (5). The data
also showed that increased ventilation was
associated with enhanced productivity. Previ-
ous reviews had indicated that there was an
increased risk of adverse health effects at out-
door airflow rates lower than 10 L/s and that
perceived air quality improved and SBS symp-
toms decreased with higher ventilation rates in
most studies (6,7). The minimum ventilation
rate set by the American Society of Heating,
Refrigeration, and Air Conditioning Engineers
is 10 L/s per person. However, European sci-
entists concluded that the risk of SBS symp-
toms increased at outdoor air-supply rates lower
than 25 L/s per person (5). Note that increasing
the outdoor air supply can result in deteriora-
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tion of indoor air quality if outdoor pollutants
are insufficiently filtered by the ventilation sys-
tem (8).
Indoor carbon dioxide (CO2) concentrations
are often used as a surrogate not only for occu-
pant-generated pollutants but also for ventilation
rate per occupant. However, CO2 concentrations
in occupied buildings usually do not reach
steady state, and for this and various other rea-
sons, CO2 concentrations may not accurately
reflect ventilation rates (6). Nonetheless, the
results of studies investigating the association
of CO2 concentrations with SBS symptoms are
generally similar to those obtained with venti-
lation rates. Analysis of data from 41 of 100 US
office buildings studied in the Building Assess-
ment Survey and Evaluation (BASE) under-
taken by the US Environmental Protection
Agency (EPA) indicated a dose–response rela-
tionship between the average workday indoor
minus average outdoor CO2 concentrations
(dCO2) and sore throat, nose or sinus symp-
toms, tight chest, and wheezing (9). The adjusted
odds ratios (ORs) per 100 ppm dCO2 ranged
between 1.2 and 1.5. When the analysis was
extended to the whole set of 100 buildings,
however, many of the previously reported
associations were not evident, and the ORs
for sore throat and wheeze were reduced to
1.15 and 1.21, respectively (10).
The rather consistent observation of a sig-
nificant negative association between ventila-
tion rate or CO2 levels and SBS symptoms
suggests that irritating compounds arising
from indoor sources play a causative role in
these symptoms and that the removal, or at
least dilution, of such chemicals should result
in a decrease of reported symptoms. It has
long been suspected that volatile organic com-
pounds (VOCs) are important contributors to
SBS, but conclusive evidence is lacking. The
VOCs may not be responsible for the SBS
symptoms; rather, the products of their reac-
tion with ozone and other chemicals may trig-
ger the symptoms. Ultrafine particles, which can
act as strong airway irritants, are one example
of these reaction products. Particulate matter
(PM) from various sources is another possible
causative agent of SBS symptoms, especially
because it has been associated with respiratory
symptoms in healthy and asthmatic subjects.
Two other groups of chemicals known to
cause some of the symptoms of SBS, phthalates
and pesticides, have received surprisingly little
attention in attempts to identify agents involved
in SBS. However, they should be an important
focus of research, given their large-scale pro-
duction and use, their known adverse effects
in experimental animals, and the growing con-
cern that they, along with other environmental
exposures, have contributed to the increasing
incidence of certain symptoms and diseases in
humans and wildlife. These other exposures
include persistent organochlorine compounds
that were widely produced and used in the
1960s and 1970s, before researchers realized
that they accumulated in the environment and
in various biota to the extent that they caused
serious adverse effects on wildlife and humans.
Their permanence ensures that humans will be
exposed to them for generations to come.
Therefore, it is important to fully understand
their health effects and, above all, their interac-
tions with the myriad of other pollutants we
produce and are exposed to in ever-increasing
amounts in the air, food, water, dust, soil, and
everything we come in contact with.
Volatile Organic Compounds
VOCs are compounds that contain at least
one carbon and one hydrogen atom, partici-
pate in atmospheric photochemical reactions,
and have a low boiling point (50–260°C), which
means they readily vaporize at room tempera-
ture. Formaldehyde is sometimes designated
as a VOC, but it is not truly a VOC because it
is a gas at room temperature. Because it also
requires different analytical techniques, it is
not as routinely measured as VOC.
Occupational exposure to VOCs and form-
aldehyde are associated with some of the same
CRIAI_31_Final Appl 7/17/06, 1:47 PM4
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symptoms as SBS (2). However, levels of these
compounds in office and other buildings are
considerably lower than those found in indus-
trial settings. Concentrations of total VOC
(TVOC) in office buildings commonly range
between less than 100 µg/m3 and several thou-
sand micrograms per cubic meter, but maxi-
mum values of up to 50,000 µg/m3 have been
reported (11,12). More than 350 VOCs have
been detected at concentrations exceeding 1
ppb in indoor air (3), but generally only about
30 to 70 are routinely measured and even fewer
are consistently detected in a majority of office
buildings (12–15).
When a group of Nordic scientists reviewed
the literature up to early 1996 regarding VOC/
TVOC and health, they concluded that neither
exposure nor epidemiological studies pro-
vided conclusive evidence that TVOC provided
a risk index for health and comfort effects in
buildings (11). A similar conclusion was reached
in a review of studies that examined the associa-
tion between SBS symptoms and indoor air-
borne PM, to which VOC can be adsorbed (16).
However, the Nordic scientists stated that indoor
air pollution, including VOCs, was most likely
causally linked to effects on health and com-
fort. They also emphasized that there were
“problems of principle with the concept of
TVOC as such” because it is poorly defined—
that is, it refers to different mixtures of chemi-
cals with varying biological effects and is used
in an unsystematic manner. Additionally, the
use of various different sampling and analyti-
cal methods constitutes a major source of vari-
ability between studies (17).
There are various other problems with the
way current assessments of factors related to
SBS symptoms are conducted. Measurements
are often taken in only a few locations in a
building, without accounting for the fact that
there are microclimates in buildings resulting
from differences in the ventilation rates, in the
number of occupants and the amount of bio-
effluents they produce, and in the furnishing
and equipment and, therefore, in the sources
of chemical compounds and their source
strength. Additionally, symptoms are gener-
ally assessed via questionnaires, and these
differ between studies and are not always
validated. The period for which symptoms are
assessed also varies from the single day on
which environmental measurements are taken
to as long as the previous year. In several stud-
ies, there is a considerable lapse of time between
these measurements and the assessment of
symptoms. The number and type of factors
included as covariates or confounders in the
statistical analysis also varies substantially
between studies. Additionally, none of the
available studies that we reviewed accounted
for the fact that people are exposed to a wide
variety of chemicals in microenvironments
other than the workplace—particularly at
home, where they spend the majority of their
time.
These considerations may explain the fre-
quent failure to detect an association between
VOC/TVOC and SBS. Various other hypoth-
eses have been proposed to explain why VOCs
may be an important factor in SBS, although
the evidence is inconclusive (18). For example,
it is possible that SBS is associated with a
subgroup or subgroups of VOCs rather than
TVOC and/or with intermediates or products
of reactions between certain types of VOCs and
ozone (O3) or various reactive oxygen and nitro-
gen species.
Principal component analysis (PCA) has
become an important tool for identifying
groups of chemicals and other factors that
could explain the different frequencies of SBS
symptoms in different buildings. It condenses
a set of highly correlated variables into a
smaller number of linearized sums (principal
components [PCs]). This works particularly
well for VOCs because subsets of them have
common sources. Because VOCs can originate
from more than one source, they can be associ-
ated with more than one PC.
PCA on a total of 39 VOCs measured in 12
California office buildings was used to identify
CRIAI_31_Final Appl 7/17/06, 1:47 PM5
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exposure metrics—that is, mathematical expres-
sions of the potential or actual agent (or combi-
nation of agents) that causes an adverse health
effect (19). The exposure metric termed irri-
tancy/PC emerged as the most significant pre-
dictor of irritant symptoms. It consisted of the
two most relevant vectors obtained by PCA,
which were identified as representing carpet
and building material emissions and emissions
from cleaning products and water-based paint;
it also accounted for the irritancy of VOCs rela-
tive to toluene. When analyzed separately, the
cleaning products and water-based paints
source vector provided the most important
symptom prediction, with statistically signifi-
cant adjusted ORs ranging from 1.7 to 2.2 for
eye, skin, throat, stuffy nose, and overall symp-
toms.
Other studies that used PCA on VOCs, but
without accounting for their irritancy, linked
photocopier emissions to mucous membrane
symptoms; paint-derived VOCs to sore throat
symptoms; construction material emission to
dry eyes, mucous membrane symptoms over-
all, and short breath; and VOCs associated with
furniture coating to shortness of breath (14,20).
A combination of PCA and partial least-
squares analysis of VOCs desorbed from dust
samples from nine office buildings identified a
set of compounds that could account for 80%
of the variance in the frequency of mucous
membrane complaints and another set of com-
pounds that explained 66% of the variance in
difficulty concentrating (21). The possibility
that oxidative degradation products of α- or β-
pinene were among the compounds associated
with mucous membrane irritation was particu-
larly intriguing. As discussed later, the oxida-
tion of terpenes produces formaldehyde and
other aldehydes, and there are indications that
some considerably more irritating substances
are also formed.
PCA was also used to identify factors that
would be able to distinguish buildings with a
high prevalence of SBS symptoms from those
with a low prevalence of SBS symptoms (22).
The most complex model was able to separate
71% of high-prevalence from low-prevalence
buildings, and the most important variable was
the higher concentration or more frequent detec-
tion of compounds with higher retention times
in gas chromatography analysis in buildings
with a low prevalence of symptoms.
However, it is unclear whether a compari-
son between buildings constitutes a meaning-
ful approach to identifying factors that predict
SBS symptoms. As Menzies and Bourbeau (2)
pointed out, three phenomena help explain
many of the features of SBS:
1. People vary in their susceptibility to vari-
ous agents.
2. There is a wide spectrum of responses to
a given agent.
3. Exposures vary considerably within large
office buildings (i.e., spatial and tempo-
ral variations in local pollutant sources
and ventilation rates may create many
different microenvironments throughout
a large building).
In five office buildings with different fre-
quencies of reported SBS symptoms, cluster
analysis was used to identify “hot” and “cold”
spots—that is, areas with high and low symp-
tom frequencies—in each building (23). Only
people working in areas where chemical and
other measurements had been taken were in-
cluded in the analysis. The most striking find-
ing was that the same factors were associated
with different symptoms and the same symp-
toms were associated with different factors in
the various buildings. Furthermore, a recent
comparison of personal exposures (measured
in the breathing zone of individual subjects) to
aldehydes, amines, NO2, O3, particles, and
VOCs in eight office buildings in a town in
northern Sweden found that intra-individual
differences accounted for the variation of 78%
of the 123 measured compounds, whereas dif-
ferences among buildings were the major
source of variability for only 14% of the com-
pounds (13). This highlights the inadequacy of
a few stationary measurements in buildings
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and underscores the need for personal expo-
sure measurements.
Weschler and Shields (24) noted that the
inability to identify irritants in an indoor set-
ting does not mean that the setting is free of
irritants but may simply reflect the difficulty
or even impossibility to detect the relevant
compound(s) with the analytical techniques
routinely used to monitor indoor air quality. It
may not be the VOCs that cause SBS symp-
toms; rather, it may be reaction products, par-
ticularly the reaction of unsaturated VOCs with
O3 and various oxygen and nitrogen radicals
(18). The major source of O3 in indoor air is
outdoor-to-indoor transport (25). Addition-
ally, office equipment, such as laser printers and
photocopiers, has been shown to emit not only
VOC but also O3 (26,27). Monoterpenes are un-
saturated VOCs that contain one or two double
bonds that react readily with O3, OH radicals,
and nitrate radicals (NO3
•) to yield various al-
dehydes, ketones, carboxylic acids, and or-
ganic nitrates (28–31).
The reaction of terpenes at concentrations
below their no observed effect level with O3
yielded reaction products that acted as strong
airway irritants in an established mouse bioas-
say (32,33). Although known irritants were
among the reaction products, they did not fully
account for the observed effect, suggesting that
one or more highly irritating intermediates
(hydroperoxides or radicals) and/or as yet uni-
dentified products were formed. A possible
candidate is submicron particles, which have
been shown to form when O3 reacts with terpe-
nes under simulated office conditions (34).
Modeling and experimental measurements
demonstrated that the product formation of
uni- and bimolecular reactions increased at
decreasing ventilation rates, whether or not
there was sufficient time for the system to
achieve steady state (35). The greatest increase
in product formation was seen when the reac-
tants originated indoors. Therefore, the decrease
in SBS symptom frequency observed with in-
creasing ventilation rates is likely to reflect not
only the removal of pollutants with indoor
sources but the restriction of reactions among
indoor pollutants.
A study of 29 office buildings in northern
Sweden is frequently cited to support the hy-
pothesis that reaction products, rather than
VOCs themselves, are associated with SBS
symptoms (36). Compared with buildings
where TVOCs were higher in the room air than
in the intake air, buildings where VOCs were
“lost” from intake to room air had an OR of 39
of being SBS buildings (36). The more TVOCs
were lost, the higher the concentration of form-
aldehyde was, providing indirect confirmation
of prior experimental data and indicating that
VOCs reacted with O3 to form various alde-
hydes, including formaldehyde (28,32,33). A
major shortcoming of this study is that VOCs
were measured up to 6 mo after SBS symptoms
had been assessed by questionnaire. Further-
more, PCA of the data from the same 29 office
buildings did not confirm the significant asso-
ciation of lost TVOCs with the prevalence of
SBS symptoms (22). However, this may have
been attributable to the simultaneous “loss”
and “gain” of TVOCs in separate rooms within
the same building.
It is rather striking that investigations of the
possible associations between VOCs and SBS
have focused exclusively on VOCs at the work-
place, although exposure occurs in almost all
microenvironments—particularly at home,
but also in cars, public transportation, restau-
rants, pubs, stores, and movie theaters (37,38).
Although rather different half-lives of elimina-
tion have been reported for VOCs from blood,
there is general agreement that VOCs are rap-
idly taken up and that their elimination is char-
acterized by a two-exponential, and in some
cases a three-exponential, equation (39). This
suggests that blood VOCs are distributed to
multiple tissues for storage and that the kinet-
ics of elimination vary with the storage site.
This is confirmed by measurements of VOCs
in breath, which suggest that under steady-
state conditions, the residence times for blood
CRIAI_31_Final Appl 7/17/06, 1:47 PM7
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or liver, organs, muscle, and fat are approx 3 min,
30 min, 3 h, and 3 d, respectively (40). From these
data, it appears possible that bioaccumulation
occurs and, therefore, that not only the kinetics
of VOC uptake and elimination but also the
threshold for adverse health effects may differ
after acute and chronic exposure. It remains to
be established whether cumulative exposure to
certain groups of VOCs is a better predictor of
SBS symptoms than exposure in the work envi-
ronment alone.
VOCs in Residential Environments
In recent years, several environmental moni-
toring studies other than those attempting to
identify factors involved in SBS symptoms
have focused on VOC exposure. A major impe-
tus for such studies was provided by the fact
that several VOCs are among the 189 hazard-
ous air pollutants listed in the US Clean Air Act
Amendment. These include the known human
(Group 1) carcinogens, benzene and 1,3-buta-
diene, and the probable human (Group 2B) car-
cinogens, styrene, methylene chloride, and
carbon tetrachloride. The International Agency
for Research on Cancer (IARC) also recently
reclassified formaldehyde from Group 2A
 (probably carcinogenic to humans) to Group 1
(carcinogenic to humans) (41).
Until recently, the majority of research on
VOCs focused on identifying exposures in out-
door air, but data on indoor residential expo-
sure to VOCs are beginning to accumulate (see
Table 2). In studies measuring personal and
residential indoor as well as outdoor concen-
trations of VOCs, personal exposure of adults
and children generally exceeded residential
indoor exposure by a substantial margin, and
indoor concentrations were considerably
higher than outdoor levels (42–45). An analy-
sis of data on personal, residential indoor and
outdoor, and work environment indoor con-
centrations of VOCs in Helsinki, Finland indi-
cated that the geometric means of residential
concentrations of VOCs exceeded those of
work environments (46). Notably, the sample
was representative of the population of Helsinki
and included people with occupational expo-
sures to VOCs, as indicated by the high maxima
reported for the work environment, which were
two orders of magnitude higher than mean
residential concentrations. A much smaller study
also indicated that many VOCs are present at
higher levels in homes than in offices (37). In the
absence of exposure to environmental tobacco
smoke (ETS), the geometric mean time-weighted
microenvironment (residential and work envi-
ronment indoor) concentrations of many VOCs
closely approximated measured personal con-
centrations of these compounds in subjects
from Helsinki (46).
Acceptable lifetime cancer risk benchmarks
(i.e., the estimated lifetime excess cancer risk
[95th percentile upper-bound] of 1 × 10–5 for an
individual exposed to this concentration for a
70-yr lifetime) have been established for vari-
ous VOCs. In a recent study that monitored
VOC exposure of 25 adults in three districts in
Minneapolis/St. Paul, only the 90th percentile
of outdoor concentrations of benzene and car-
bon tetrachloride exceeded such benchmark
concentrations (42). Conversely, even the median
personal and residential indoor concentrations
of benzene exceeded the benchmark, and the
90th percentile indoor and personal exposure
levels were higher than the risk threshold for
three of the other five VOCs for which bench-
marks are available. Similarly, in the SHIELDS
study of children from two inner-city schools
in Minneapolis, researchers found that median
indoor residential and personal exposure lev-
els of p-dichlorobenzene and benzene were
above the acceptable risk thresholds during at
least one of the seasons of measurement (45).
Other hazardous air pollutants listed in the
Clean Air Act Amendment, such as styrene,
benzaldehyde, phenol, 2-butoxyethanol, and
hexanal, are mucous membrane irritants, al-
though at far greater concentrations than are
generally encountered in indoor environments.
2-Butoxyethanol and oxidation products of D-
limonene are skin-contact allergens (47).
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Formaldehyde
Formaldehyde is well-established as an irri-
tant of the eye and upper respiratory tract. It
was recently reported that formaldehyde at a
concentration of 0.1 µg/mL increased the expres-
sion of intracellular adhesion molecule (ICAM)-
1 and vascular adhesion molecule-1 on human
mucosal microvascular endothelial cells to an
extent similar to the combination of interleukin
(IL)-4 and tumor necrosis factor (TNF)-α (17a).
It also promoted adhesion of eosinophils iso-
lated from patients with allergic rhinitis to
these cells. No induction of adhesion molecules
was observed with the VOCs; 1,2-, 1,3-, or 1,4-
benzene; o-, m-, or p-xylene; or toluene at the
same concentration. These observations might
explain the finding of an increased number and
proportion of eosinophils in nasal lavage fluid
of healthy volunteers up to 18 h after exposure
to 0.5 mg/m3 of formaldehyde for 2 h (48). In
Swedish school personnel, formaldehyde con-
centrations were significantly associated with
decreased nasal patency (measured by acoustic
rhinometry) and increased levels of the inflam-
matory markers eosinophil cationic protein
(ECP) and lysozyme, but not myeloperoxidase,
in nasal lavage (49).
There are increasing indications that form-
aldehyde not only affects the upper respiratory
tract but that it can also enhance allergic sensi-
tization and, through this and possibly other
mechanisms, can cause lower respiratory tract
symptoms, including asthma. Formaldehyde
has been shown to enhance sensitization in
ovalbumin (OVA)-immunized guinea pigs
(50–52). Although chronic inhalation of form-
aldehyde does not appear to induce significant
inflammation in the lower respiratory tract of
nonsensitized mice (53) or guinea pigs (50),
it has been shown to increase the number of
inflammatory cells in bronchoalveolar lavage
fluid of OVA-immunized mice (53) and to poten-
tiate allergen-induced bronchoconstriction in
OVA-immunized guinea pigs (50).
Occupational or accidental exposure to
formaldehyde occasionally has been associated
with the development of asthma that can per-
sist even after further exposure to formalde-
hyde is avoided (54,55). In some of these cases,
specific inhalation challenges identified form-
aldehyde resin dust, but not gaseous formal-
dehyde, as the cause of asthma symptoms (55).
Whereas formaldehyde gas is largely absorbed
in the upper respiratory tract, formaldehyde in
particulate form could reach the lower respira-
tory tract, which could explain its greater ability
to cause airway responses. Because products
made from urea–formaldehyde resins, such as
particleboard and medium-density fiberboard,
are used extensively in the construction of new
houses, formaldehyde resin dust may also be
in residential environments. Although wood
products are the sources that emit the highest
amounts of formaldehyde, a wide variety of
other products also contribute to indoor form-
aldehyde pollution (see Table 3; ref. 56). ETS is
another important source of formaldehyde.
Mean or median residential indoor formal-
dehyde concentrations of 15 to 30 µg/m3 have
been reported in several recent studies from
the United States (57) and Australia (58,59).
Maxima ranged between 139 and 408 µg/m3,
indicating that some homes largely exceed cur-
rent indoor guidelines (e.g., 120 µg/m3 in Aus-
tralia at the time). Notably, with increasing
awareness of the adverse health effects of
formaldehyde, the guideline values have
been steadily decreasing. Currently, the low-
est guideline value is the chronic inhalation ref-
erence exposure level of 3 µg/m3 set by the
Office of Environmental Health Hazard Assess-
ment of the California EPA. Chronic relevance
exposure levels are concentrations or doses at
or below which adverse health effects are not
likely to occur.
Despite the relatively low concentrations of
formaldehyde in homes compared with occu-
pational exposure levels, chronic domestic or
other indoor exposure to this chemical can result
in sensitization to formaldehyde itself (60,61)
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Table 2
Residential VOC Levels (in µg/m3)
71 Homes in three
urban neighborhoods 170 Homes in Arizona (57),
in Minneapolis/ 113 Homes in 284 Households in but much smaller n for
St. Paul (42) Minneapolis (45)a Minnesota (44) many of the VOC
Integrated 8-h sample over a
2-d Charcoal-based 2-d Charcoal-based 6-d Charcoal-based 24-h sampling period; mixture
passive sampling passive sampling passive sampling of active and passive sampling
Benzene (%) 100 100 100 49
Median 1.9 2.2 3.3 1.3
P90 15.3 6.2 12.7b 9.5
Carbon tetrachloride (%) 99.2 99
Median 0.5 0.6
P90 0.9 0.6
Chloroform (%) 75.3 98 98.6
Median 0.9 0.8 1.7
P90 3.4 2.6 5.7b
p-Dichlorobenzene (%) 72.6 82.8 88
Median 0.2 0.7 0.5
P90 1.5 344.6 3.4b
Ethyl benzene (%) 99.0 100
Median 1.4 1.0
P90 8.9 2.8
D-Limonene (%) 99.6 100
Median 9.0 28.6
P90 30.7 122.3
Methylene chloride (%) 97.9 23.2
Median 1.1 0.4
P90 11.5 1.3
α-Pinene (%) 99.6 100
Median 2.5 2.4
P90 12.4 6.5
β-Pinene (%) 71.0 94.9
Median 1.2 2.5
P90 5.2 11.7
Styrene (%) 74.3 91.9 84.9
Median 0.5 0.7 0.9
P90 1.4 1.5 2.4b
Tetrachloroethylene (%) 97.6 98 86.6
Median 0.6 0.5 1.4c
P90 3.8 1.3 4.9b
Toluene (%) 97.9 100 99.6 86
Median 12.3 8.2 16.2 10
P90 53.8 19.2 63.0b 49
Trichloroethylene (%) 83.9 82.8 94.0 1
Median
P90 0.8 0.9 1.4b <1.8
o-Xylene (%) 99.7 100 100
Median 1.6 1.2 2.1
P90 11.4 3.2 6.8b
m-/p-Xylene (%) 99.7 100 100
Median 4.8 3.7 4.6
P90 36.9 10.4 21.6b
Total VOC (%)
Median
P90
GM, geometric mean; DL, detection limit.
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Table 2 (Continued)
Residential VOC Levels (in µg/m3)
40 Households
201 Households in Oxford,
in Helsinkki, 796 Households United Kingdom 317 Households Perth,
Finland (46) in England (73) (373) in Japan (67) Western Australia (66)
48-h Tenax TA 4-wk Tenax TA 2-d Tenax TA 1-wk Charcoal-based 8-h Active sampling,
active sampling passive sampling active sampling passive sampling charcoal sorbent tubes
Cases Controls
71 70 86
GM 1.57 3.3 GM 2.6 24.8 11.8
4.2 14.6b 46.8 31.7
N/A
Mean 26.7 0.01 0.01
Max 1029 6.7 5.0
94 28 N/A
GM 2.17 GM 1.6 Mean 18.7 1.4 0.8
5.79 Max 278.1 3.6 3.6
99
GM 11.57 7.1 Mean 25.0
80.65 51.0b Max 138.8
100 70
GM 9.09 GM8.7 Mean 27.5
38.37 Max 218.9
50 13 N/A
GM 0.84 No GM because Mean 13.1 0.01 0.01
<20% above DL
2.17 171.3 1.3 0.8
9 3%
c No GM because Mean 5.1
<20% above DL
1.10 Max 46.9
100 88 99
GM 14.62 14.9 GM 12.1 Mean 326 11.9
37.39 74.9b Max 3105 36.9
3 13
No GM because
<20% above DL
0.89
93 13
GM 1.88 No GM because
<20% above DL
4.25
99 63
GM 6.13 3.7 GM 4.8
14.82 30.3b
N/A
202 GM 194 Mean 482.6 78.5 36.2
1010b Max 3278 204.6 101.0
aThe winter values are listed, which are generally somewhat higher than the measurements obtained in spring.
bValues are the 95th percentile rather than the 90th percentile, as in most other studies.
cNot reported because the compound was detected in less than 20% of samples
GM, geometric mean; DL, detection limit.
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Table 3
Sources of Formaldehyde and VOCs
Chronic inhalation Rel
Compound Sources (OEHHA) (µg/m3)
Formaldehyde Most important and highest-emitting sources are particle- 3
board and medium-density fiberboard fabricated with
urea–formaldehyde resins; fiberglass insulation, paper
products, combustion of gas and solid fuels, ETS, personal
computers (PCs), paints, cleaning products, cosmetics
VOCs Combustion products, including traffic emissions and ETS,
solvents, floor adhesives, paint, furnishings, photocopiers
and PCs, cleaning products, air fresheners, hair spray,
moth balls
Benzaldehyde Building-related materials such as linoleum; molds and fungi N/A
Benzene Combustion products, particularly ETS; paints, wood 60
p-Dichlorobenzene Moth cakes, air fresheners, toilet bowl deodorizers 800
Ethylbenzene Combustion products, including ETS; paints or lacquers 2000
Ethylene glycol, Latex paint 400
propylene glycol (N/A for propylene
glycol)
D-Limonene, α- Cleaning products, air fresheners, waxes, polishes, plywood N/A
and β-pinene
Toluene Paints, lacquers, printing ink, adhesives, PCs 300
Styrene Combustion products, including ETS; adhesives, carpeting, PCs 900
m/p-, o-xylene Combustion products, including ETS; printing ink 700
Naphthalene Combustion products, including ETS; moth balls 9
n-decane, Sheet vinyl flooring N/A
n-dodecane,
n-tridecane,
n-tetradecane
OEHHA, Office of Environmental Health Hazard Assessment of the California Environmental Protection Agency.
and can enhance the incidence and severity of
atopic sensitization to common allergens (58,62).
Importantly, residential formaldehyde expo-
sure has been associated with inflammation of
the lower respiratory tract as well as asthma
and other lower respiratory tract symptoms in
children and adults. Concentrations of exhaled
nitric oxide (NO), which is believed to repre-
sent a marker of pulmonary inflammation, were
found to be significantly higher in healthy chil-
dren age 6 to 13 yr who were exposed to resi-
dential concentrations of formaldehyde of 50
ppb (62 mg/m3) or greater compared to those
exposed to levels less than 50 ppb (63). The tech-
nique used in this study ensured that the exhaled
NO originated from the lower respiratory tract.
This suggests that formaldehyde exposure
may have induced an inflammatory response,
even in children without signs or symptoms of
upper or lower respiratory tract disease.
The prevalence of asthma and chronic bron-
chitis was significantly greater in children, but
not adults, from homes with formaldehyde con-
centrations greater than or equal to 60 ppb
(approx 74 µg/m3) compared with those exposed
to lower levels (64). A linear decrease in peak
expiratory flow rates (PEFRs) was observed
with increasing formaldehyde exposure. A study
of Swedish adults found significantly higher lev-
els of both VOCs and formaldehyde in connec-
tion with indoor painting within the last 12 mo,
and, in turn, exposure to recently painted sur-
faces was associated with increased symptoms
related to asthma and current asthma (defined as
bronchial hyperresponsiveness) as well as at least
one asthma-related symptom in adults (65).
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In young children (age <3 yr) who were dis-
charged from the emergency department with
asthma as the primary diagnosis, there was a
significant association between case status
and higher residential formaldehyde expo-
sure compared with age-matched controls (59).
In the same group of children, a significant cor-
relation was also detected between total and
individual domestic VOC levels and asthma;
benzene, ethylbenzene, and toluene were each
associated with significantly increased ORs
(66). Note that it is difficult to determine
whether wheezing illness in such young chil-
dren truly constitutes asthma. Total VOCs
measured in 96 Japanese homes carried signifi-
cantly elevated ORs for throat and respiratory
symptoms in the 317 residents of these build-
ings (67). Xylene, α-pinene, and nonanal were
the three individual VOCs significantly associ-
ated with these symptoms. An association
between VOC exposure and asthma has fur-
ther been suggested by the finding that urinary
concentrations of muconic acid and 1-hydroxy-
pyrene (metabolites of VOCs and polycyclic
aromatic hydrocarbons, respectively) were
elevated in children with asthma compared
with children without wheezing episodes or
atopic diseases (68).
In partial contrast, in a study of 193 chil-
dren with persistent wheezing illness and
223 controls age 9 to 11 yr, no association was
detected between formaldehyde or individual
or total VOCs and case status (69). However,
the frequency of nocturnal symptoms (wheez-
ing, chest tightness, breathlessness, or cough)
was associated with formaldehyde exposure
but not with VOC concentrations. In Swedish
adults, nocturnal breathlessness was signifi-
cantly associated with both the formaldehyde
and the VOC concentrations in their homes (70).
Residential formaldehyde exposure was
not significantly associated with the risk of
asthma or respiratory symptoms in a group of
148 Australian children age 7 to 14 yr, although
the maximum recorded formaldehyde values
of four 4-d samples were associated with atopic
sensitization (58). Note that this is one of the
few studies in which exposure was measured
on several occasions through the year. In most
studies, only single measurements of formal-
dehyde and/or VOCs were taken. Therefore,
in our opinion, the associations with allergic
sensitization or asthma observed in such stud-
ies should be interpreted with considerable
caution.
The limited data available indicate that
there are substantial day-to-day, daytime vs
nighttime, and seasonal fluctuations in VOC
exposure resulting not only from changes in
the environment over time but also from dif-
ferences in sources and activities that result in
exposure (46,71). Intra-individual variation
over multiple monitoring periods was found
to span two orders of magnitude for each of
the 14 VOCs measured in personal air (72).
Additionally, residential indoor VOC concen-
trations are consistently lower than levels mea-
sured in the personal air space of both adults
and children (42–45), indicating that they do
not fully reflect personal exposure. Further-
more, it is not clear whether peak exposure or
chronic low-level exposure constitutes a greater
risk for atopy and asthma.
Concentrations of indoor VOCs and form-
aldehyde generally exceed outdoor concentra-
tions by as much as an order of magnitude
(42–45). This clearly shows that they are emit-
ted from indoor sources and are not trans-
ported in from the outside. Sources, rather than
types and rate of ventilation, were associated
with indoor formaldehyde, VOC, CO, and NO2
levels in homes (ref. 73; see Table 3 for common
formaldehyde and VOC sources). This was at
least partly confirmed by a Finnish study of
VOCs that combined personal exposure assess-
ment with measurements in residential and
work environments (46). ETS was found to be
a dominant source of personal VOC exposure.
In ETS-free homes, variability in VOC exposure
stemmed from compounds associated with
cleaning products, followed by compounds
associated with traffic emissions, long-range
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transport of pollutants, and product emissions
(74). Together, these data suggest that source
control constitutes the most effective way of
reducing environmental exposure to formalde-
hyde and VOCs.
Phthalates
Phthalates are dialkyl- or alkylarylesters of
1,2-benzenedicarboxylic acid. The major repre-
sentative is di(2-ethylhexyl) phthalate (DEHP),
of which the worldwide annual consumption
exceeds two million tons (75). Waste that
contains DEHP is estimated to emit another
100,000 tons of DEHP annually. Total world-
wide phthalate consumption is estimated at
3.25 million tons.
DEHP and other phthalates are used as
plasticizers in polyvinyl chloride (PVC) prod-
ucts, which may contain up to 40% DEHP. PVC
resins are used to manufacture a wide variety
of items, including floor tiles, vinyl upholstery,
toys, disposable medical examination and sur-
gical gloves, medical tubing, blood storage
bags, components of paper, and paperboard.
Additionally, phthalates are used as fixatives,
detergents, lubrication oils, and solvents as
well as in cosmetics and personal care prod-
ucts. Because phthalates are not covalently
bound to PVC-based products, they leach and
vaporize from plastic over time.
Exposure Routes
The main exposure route is generally as-
sumed to be ingestion, with fatty foods, such
as dairy, fish, meat, and oils containing the
highest levels, whereas inhalation and dermal
contact make lesser contributions (76–82). How-
ever, in the case of diethyl phthalate (DEP) used
in personal care products, dermal absorption
can probably substantially contribute to total
exposure. Recently, the detection of several
phthalate metabolites was reported in hu-
man breast milk, indicating that oral exposure
can begin immediately after birth (83). Addi-
tionally, direct intravenous exposure occurs
in patients undergoing dialysis or receiving
blood transfusions.
Note that there is limited evidence to sup-
port the hypothesis that food constitutes the
major source of phthalates (84). Rather, a recent
study found a significant correlation between
the concentrations of di-n-butyl (DBP), butyl
benzyl (BBzP), and DEP in inhaled air and their
urinary monoester metabolites (85). Correla-
tion coefficients ranged from 0.65 for BBzP to
0.42 for DEP. Substantial amounts of various
phthalates were also found to be adsorbed to
suspended PM and may make even greater
contributions to inhalation exposure than
phthalates in the vapor phase (86). Together,
these results suggest that inhalation may rep-
resent an important exposure route for at least
some phthalates. Tables 4 and 5 summarize
measurements of various phthalates in air and
dust of residences, schools, and day care centers.
The ubiquity of phthalates and the result-
ing high level of contamination of laboratory
equipment made it difficult to assess the extent
of exposure until measurement of monoester
metabolites was introduced (87). After oral
ingestion, phthalate diesters are hydrolyzed to
their respective monoesters. The relatively
polar and low-molecular-weight phthalates
are excreted primarily as monoesters. The mo-
noesters of phthalates with higher molecular
weights, such as DEHP, di-n-octyl phthalate,
and di-isononyl phthalate, undergo rather exten-
sive ω-1 and ω-oxidation of their aliphatic side-
chains (88,89). In humans, monoesters and the
oxidative metabolites are excreted primarily as
glucuronides (89,90). Despite their lipophilic
nature, phthalates are metabolized and excreted
in feces and urine within 3 d; consequently,
bioaccumulation is not believed to be a prob-
lem.
Studies measuring urinary monoester
metabolite concentrations have revealed higher
and more widespread phthalate exposure than
had previously been suspected (see Table 6).
Notably, several studies have indicated that
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concentrations of most urinary phthalate me-
tabolites are significantly higher in children than
in adults (91,92). There is growing evidence
that some secondary oxidative metabolites of
DEHP, such as mono-(2-ethyl-5-hydroxyhexyl)
phthalate (5-OH-MEHP) and mono-(2-ethyl-5-
oxohexyl) phthalate (5-oxo-MEHP), are present
in urine in considerably higher concentrations
than mono-(2-ethylhexyl) phthalate (MEHP)
(4.5- and 3.5-fold higher, respectively; refs.
88,89, and 93; see also Table 6). They and other
recently identified metabolites may constitute
more sensitive biomarkers of exposure to DEHP
(94,95).
Extrapolation of daily phthalate intake from
urinary excretion of their metabolites is ham-
pered by several factors. Urinary phthalate
metabolite levels have been found to vary with
the time of sample collection (92,96). Further-
more, substantial within-subject variability has
been observed, and researchers have calculated
that up to four samples obtained 1 to 3 mo apart
may be necessary to classify exposure with a
reliability of 80% (97,98). Another difficulty in
estimating daily phthalate intakes from uri-
nary excretion of their metabolites is the lim-
ited availability of fractional excretion data.
This is illustrated by the vast differences (10.3
vs 1.76 µg/kg/d) in the estimates of median
daily DEHP intake obtained using the same
data but different assumptions of the fractional
excretion of MEHP (99,100). Note that if the
higher estimate were correct, up to 31% of the
metabolite values would yield intake estimates
exceeding the reference dose (RfD) of 20 µg/
kg of body weight/d set by the US EPA, and
12% of intake estimates would exceed the tol-
erable daily intake (TDI) value of 37 µg/kg/d set
by the corresponding European Union agency.
Table 7 summarizes daily intake estimates for
DEHP and other common phthalates.
Considerable amounts of phthalates can
leach from the bags and tubing used for vari-
ous medical procedures, such as hemodialysis,
and parenteral nutrition (101). The resulting
high levels of exposure experienced by neo-
nates in intensive care have long been of par-
ticular concern because the rapid growth and
development of neonates, combined with the
immaturity of their detoxification enzyme sys-
tems, makes them particularly vulnerable. A
recent small study of six premature neonates
in intensive care units (102) found 22-fold
higher mean urinary MEHP concentrations com-
pared to California toddlers (91) and 26-fold
higher median MEHP concentrations than
were reported for 6- to 11-yr-old children in
NHANES III (ref. 92; see also Table 6). Daily
intake may exceed 4 mg/kg/d in infants receiv-
ing exchange transfusions, whereas patients
with adult hemodialysis may be exposed to up
to 3 mg/kg/d (103).
It was also feared that mouthing of plastic
toys would result in significant phthalate expo-
sure in small children, and many American
manufacturers voluntarily discontinued the
use of DEHP in plastic toys for small children.
However, a recent risk assessment, estimated
that exposure of children age 12 to 23 mo by
this route was an average of 0.08 µg/kg/d
(95% confidence interval 0.04–0.14) and con-
cluded that chewing soft plastic toys was not
likely to present a health hazard (104).
Although urinary excretion of phthalate
metabolites constitutes a noninvasive method
for assessing exposure, the need to correct for
dilution and the uncertainty of available frac-
tional excretion data represent serious draw-
backs. Serum concentrations of phthalate ester
metabolites allow more direct exposure assess-
ment. In serum and breast milk, however, even
the measurement of monoester metabolites can
yield artificially elevated results because of the
presence of lipases capable of mediating the
conversion of the parent phthalates into their
respective monoesters (83,105). This problem
may be circumvented by the use of secondary
metabolites arising from the oxidative metabo-
lism of the monoester, such as 5-OH-MEHP
and 5-oxo-MEHP in the case of DEHP (89).
Unfortunately, conversely to urine, these oxi-
dative metabolites do not constitute the major
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metabolites in serum (94) and are not as fre-
quently detectable as MEHP (89).
Inhalation Exposure and Respiratory
Symptoms
Animal studies have shown that DEHP,
MEHP, and DBP—but not BBzP—have adju-
vant properties in terms of IgE and IgG1 pro-
duction when injected subcutaneously together
with OVA (106–108). Findings suggestive of
enhanced sensitization have also been reported
in humans, but the activity pattern of phtha-
lates was quite distinct. Specifically, results
from a Swedish case–control study indicated
a significant association between physician-
diagnosed rhinitis or eczema and BBzP in dust
from the child’s bedroom, whereas DEHP was
associated with physician-diagnosed asthma,
and DEP showed no association with either
disease (ref. 109; see Table 4 for phthalate concen-
trations in dust). The association of individual
phthalates with different symptom outcomes
may be a reflection of their different physical
properties, including vapor pressures, polari-
ties, and octanol/air partition coefficients. Nota-
bly, median concentration of DEHP and BBzP
were significantly higher in bedrooms with
PVC flooring, and a correlation between PVC
flooring and case status was also observed in
this study, although it was weaker than the asso-
ciations observed with DEHP and BBzP. This
confirms the results of an earlier case–control
study that indicated an association of PVC
flooring and other plasticizer-containing sur-
faces with bronchial obstruction in 2-yr-old
children in Oslo (110). The association was
found to be considerably stronger in children
from homes with low air exchange rates com-
pared with those with high air exchange rates,
suggesting that chemical compounds in the
vapor phase or adsorbed to suspended par-
ticles were involved in the observed associa-
tions (111). In a previous study by these
investigators, DEHP and BBzP concentra-
tions in sedimented dust and suspended PM
were highly correlated (86). Dust has been
shown to increase the DEHP emission rate
from PVC floors and its deposition on internal
surfaces (112). In addition to PVC floors, the
amount of plastic wall materials was found to
be associated with persistent wheezing, cough,
and phlegm in a cross-sectional study of chil-
dren age 1 to 7 yr (113).
An exploratory study examined associa-
tions between phthalate exposure as measured
by urinary phthalate metabolites and pulmo-
Table 7
Estimated Daily Phthalate Intake (in µg/kg/d)
David (627) Kohn et al. (628) Koch et al. (99) German data
based on NHANES based on NHANES data on general recalculated by
Phthalate subsample (90) subsample (90) German population David (627)
GM P95 Median P95 Median P95 Median
DEHP 0.60 3.05 0.71 3.6 10.3a 38.3a 1.76
DEP 12.34 93.33 12 110 2.32 22.1
DBP 1.56 6.87 1.5b 7.2b 5.22b 16.2
BBzP 0.73 3.34 0.88 4.0 0.60 2.52
DOP (di-n-octyl) 0.0096 0.96 <LOD 0.42
DINP 0.21 1.08 <LOD 1.7
aThese values are based on MEHP excretion; they were 13.8 and 52.1, respectively, when using the average of 5-
OH-MEHP and 5-oxo-MEHP
bNote that Kohn et al. (628) and Koch et al. (99) used the same fractional excretion values of calculating DBP and
BBzP intake. Because values for DBP still differ markedly, there may be true differences in intake in the two popula-
tions.
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nary function parameters in a subsample of 240
adults who participated in NHANES III (114).
There were significant negative associations
between mono-n-butyl pthalate (MBP) and
forced vital capacity (FVC), forced expiratory
volume after 1 s (FEV1), and peak expiratory
flow (PEF) in males only. The effect on FVC
was essentially confined to nonsmoking males.
An association between monoethyl phthalate
and lower FVC and FEV1 was also observed
only in males. Conversely, in nonsmoking
women, FEV1 and maximum midexpiratory
flow correlated positively with MEHP concen-
trations.
Under alkaline conditions, DEHP is de-
graded into MEHP and 2-ethyl-1-hexanol, and
the latter is reportedly used in Sweden as an
indicator of alkaline degradation of DEHP
(115). A geometric mean 2-ethyl-1-hexanol con-
centration of 2.47 µg/m3 was reported in Finn-
ish homes, and the geometric mean personal
exposure was only slightly higher (2.63 µg/m3;
ref. 46) and similar to the geometric mean of
3.0 µg/m3 reported for a German population
(116). Findings suggestive of an association
between one or both of the DEHP breakdown
products, MEHP and 2-ethyl-1-hexanol, with
an increased prevalence of self-reported and
objective ocular and nasal symptoms have
been reported in workers at four Swedish hos-
pitals (115).
Together, these results suggest that phtha-
late exposure may play a role in SBS symptoms
both directly (by causing lower respiratory
symptoms) and indirectly (by enhancing atopic
sensitization and asthma), both of which are
associated with higher frequencies of SBS
symptom reporting (10,14,117).
Reproductive Toxicity
Under the auspices of the NTP Center for
the Evaluation of Risks to Human Reproduc-
tion, a panel of experts assembled compre-
hensive reviews of the literature published
through 2000 concerning the reproductive
toxicity of phthalates (76–82). Of this group of
compounds, only gestational exposure to
DEHP, BBzP, DBP, and, with far lesser potency,
di-isononyl phthalate induced defects of the
male reproductive organs in rats, mice, rabbits,
and—to a far lesser degree—hamsters. The
extent and severity of male reproductive tox-
icity depended greatly on the dose, timing, and
duration of exposure and the route and vehicle
of administration. Effects on reproductive
parameters have also been observed following
administration during prepuberty, whereas
adult exposure has resulted in adverse effects
on the male reproductive system only at very
high doses.
Few effects of prenatal or prenatal plus lac-
tational exposure to phthalate esters have been
reported in female offspring, but several recent
studies indicated that DBP induced isolated
instances of reproductive tract malformations
(118), significantly delayed vaginal opening
and occurrence of first estrous (119), decreased
pituitary weights, and increased the incidence
of hypoplasia of the alveolar buds of the mam-
mary glands (120). Nonetheless, the male repro-
ductive organs appear to be markedly more
sensitive to the effects of phthalates.
Since the aforementioned reviews, the male
reproductive toxicity of DEHP, BBzP, and DBP
has been confirmed and extended to the dem-
onstration of significant effects, even with
markedly lower doses or considerably shorter
dosage regimens than had previously been
used (119–124). Decreases in sperm count and
motility and an increased incidence of morpho-
logically abnormal sperm are among the most
sensitive indicators of the male reproductive
toxicity of phthalates (77–79,120,123,125). The
defects observed in the male reproductive organs
include hypospadias, cryptorchidism, testicu-
lar atrophy, underdeveloped or absent epid-
idymis, irreversible degeneration and atrophy of
seminiferous tubules, reduced anogenital dis-
tance, and retained nipples/areolae (77–79).
In other words, they involve the testosterone-
dependent differentiation of the Wolffian ducts
into epididymides, vasa deferentia, seminal
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vesicles, and normal development of fetal tes-
tes; acquisition of preputial separation and onset
of spermatogenesis; and the dihydrotestosterone
(DHT)-dependent development of male exter-
nal genitalia and the prostate, regression of
nipples/areolae, and anogenital distance.
Recent studies have indicated that in addi-
tion to testosterone- and DHT-dependent pro-
cesses, insulin-like hormone 3 (Insl3)-dependent
processes are also affected by exposure to phtha-
lates that are toxic to the male reproductive
organs. Insl3 is produced by Leydig cells and
regulates the development of the gubernacu-
lum, which in turn is critical for testicular descent
first into the lower abdomen to the inguinal ring
and later into the scrotal sacs. A pronounced
reduction of Insl3 messenger RNA (mRNA)
was observed in testes of male gestation day
(GD) 18 fetuses from dams exposed to 1000
mg/kg of DEHP, DBP, or BBzP from GDs 14 to
18; DBP and BBzP were more effective than
DEHP (126). Similarly, Insl3 mRNA levels and
immunoreactive Insl3 in interstitial cells in tes-
tis collected on GD 19 were significantly reduced
in fetuses whose dams were exposed to 500 mg/
kg/d of DBP, although not at lower doses (100,
10, 1, or 0.1 mg/kg/d) from GD 12 through
GD19 (127).
The malformations in androgen-dependent
tissues in male rat offspring of mothers treated
with DBP or DEHP resemble those induced by
well-known anti-androgens, such as vinclozolin
or flutamide (118). However, they do not appear
to be mediated by the androgen receptor (77–
79,128,129). Rather, numerous studies have
shown that gestational exposure to DEHP (126,
128,130), DBP (121,126,127,131,132), and BBzP
(126,133) as well as their common metabolite
MBP (124) induces a marked decrease in tes-
ticular testosterone production and levels of
serum testosterone concentrations. In a direct
comparison, DBP and BBzP were more effec-
tive than DEHP (126). These decreases do not
appear to be permanent when exposure is lim-
ited to the gestational period (121,130).
Developmentally toxic phthalates not only
affect Leydig cells but alter the structure and
function of Sertoli cells, which have been pro-
posed to be the actual primary target (77–79).
Whereas some recent research have failed to
find direct or indirect evidence of alterations
in Sertoli structure and function (118,124,128),
cell-specific immunohistochemistry has revealed
that maturation of Sertoli cells was incomplete
in male fetuses exposed to DBP starting at GD
13 (121). During fetal development, Sertoli cells
secrete paracrine factors that are essential for
the differentiation and testosterone production
of Leydig cells. Therefore, the immaturity of
Sertoli cells and resulting disturbances in Ser-
toli-Leydig cell signaling could explain the
marked reduction in testosterone synthesis by
fetal Leydig cells. Such decreased testosterone
production is frequently seen in conjunction
with Leydig cell hyperplasia (121,128,132,134).
This has been suggested to constitute a com-
pensatory mechanism to maintain testosterone
output (132). Alternatively, the reduced test-
osterone and Insl3 production after gestational
exposure to phthalates could delay Leydig cell
maturation and differentiation, thereby pro-
longing their proliferation and resulting in
hyperplasia (126).
Several recent studies have used microarray
and reverse transcriptase polymerase chain
reaction to investigate changes in the gene
expression profile in the testes following in
utero exposure to phthalates. In some cases,
this was accompanied by immunohistochemi-
cal analysis of changes in protein expression.
Interestingly, the phthalates known to be repro-
ductive toxicants all induced very similar alter-
ations in gene expression, whereas no significant
changes were observed after exposure to the
nondevelopmentally toxic phthalates (135).
Consistently with the previously observed
decrease in testicular testosterone produc-
tion, the genes and gene pathways involved in
steroidogenesis and cholesterol homeostasis
and transport were found to be major targets
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and were all downregulated (127,131,134,135).
The effects of DBP on the expression of genes
involved in cholesterol transport and steroido-
genesis were dose-dependent, with significant
reductions in mRNA levels of scavenger recep-
tor B type 1 and 3β-hydroxysteroid dehydroge-
nase observed at doses of 0.1 and 1.0 mg/kg/d,
respectively (127).
Conversely, several genes regulating cell
proliferation and survival were upregulated
(127,131,134,136), which is consistent with the
observed Leydig cell hyperplasia. Other targeted
genes and gene pathways included α-inhibin,
which is essential for normal Sertoli cell devel-
opment and insulin signaling (135). Within the
Wolffian duct, exposure to DBP from GDs 15
to 19 or 21 altered the expression of genes
within the insulin-like growth factor pathway
and other developmentally important signal-
ing pathways as well as genes for extracellular
matrix components (137). These findings sug-
gest a model in which prenatal DBP exposure
disrupts orchestrated molecular responses
between epithelia, mesenchyme, and extracel-
lular matrix, thereby altering Wolffian duct
morphology. These alterations are likely to be
secondary to decreased testosterone synthesis
but could also be mediated more directly.
Reduced testicular testosterone production
and concentration have also been shown to oc-
cur in prepubertal rats (130,138). A comparison
of different windows of exposure indicated that
DEHP had differential effects during gestation,
lactation, prepuberty and young adulthood,
with decreasing effects observed with increas-
ing age (130,136). Additionally, different dura-
tions of DEHP treatment were associated with
either up- or downregulation of Leydig cell tes-
tosterone synthesis, whereas serum levels
did not necessarily change in the same direc-
tion and apparently depended on the differen-
tial effects that various durations of DEHP
exposure had on enzymes and hormones regu-
lating testosterone synthesis and metabolism
(130,136,138).
Relevance to Humans
The proximate developmental toxicants of
phthalates in rats and mice are believed to be
their respective monoesters. After oral expo-
sure, gut lipases and esterases hydrolyze ph-
thalate esters into their more easily absorbable
monoesters. Pronounced interspecies differ-
ences exist in lipase activity, with primates
exhibiting much lower activity than rats and
having correspondingly lower dose-normal-
ized monoester levels (77). Consequently, a
default risk assessment, consisting of the low-
est observed adverse effect level multiplied by
default factors of 10 each for interspecies and
interindividual differences, was deemed inap-
propriate (139). A recent direct comparison
confirmed that oral treatment with equal doses
of DEHP per unit of body weight resulted in
up to 7.5 times lower peak concentrations of
MEHP in marmosets than in rats (140). Nor-
malized areas under the curve were up to 16
times lower in the primates. However, a human
volunteer who consumed an almost 50-fold-
lower dose of DEHP (0.65 mg/kg) than the
lowest dose used in the study of marmosets
and rats (30 mg/kg) had a similar Cmax of
MEHP (2.5 mg/L compared with 2.7 mg/L in
marmosets) (94). Additionally, the dose-nor-
malized area under the curve for this volun-
teer was at least 15 times higher than in the rats
and almost 100 times higher than in the mar-
mosets. Although this is only based on a single
individual, it certainly does not suggest that
human tissues are exposed to lower concentra-
tions of MEHP than rats after the same dose of
DEHP.
It has been proposed that the unconjugated
monoesters are the mediators of reproduc-
tive toxicity in rats (141) because monoesters
undergo little glucuronidation in these ani-
mals. Conversely, in humans, the majority of
phthalate monoesters and even the secondary
metabolites are present in urine in the form of
glucuronides (89,90). In serum, the metabolites
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(at least of MEHP) were reported to be mostly
conjugated (89), but this is in marked contrast
to the findings from a single human volunteer
(142). Note that this volunteer had ingested a
high dose of DEHP, and researchers recently
showed that, at least in urine, free MEHP made
up 3% of total MEHP at the 50th percentile con-
centration but made up almost 87% at the 95th
percentile (141). This correlation was not sta-
tistically significant for MEHP, but there was
a linear increase in the percentage of free
monoethyl phthalate (MEP), MBP, and mono-
benzyl phthalate (MBzP) in urine with increas-
ing total forms. This could indicate that the
difference between the findings in a single vol-
unteer and those of the larger study resulted
from the higher dose the volunteer ingested.
However, it could also be a reflection of vari-
ability in phthalate metabolism, because sub-
stantial interindividual variation has been
reported in the degree of conjugation (141).
Notably, in the investigation of urinary phtha-
late monoester metabolites in a subsample of
NHANES III, 5% of urine samples from 289
subjects had markedly elevated concentra-
tions (67% above the next lowest level) of
unconjugated monoesters (90).
In addition to glucuronidation, MEHP
undergoes extensive oxidative metabolism in
humans (88,89). Nanomolar concentrations of
two of the oxidative metabolites of DEHP, 5-oxo-
MEHP and 5-OH-MEHP, were recently reported
to inhibit DTH-induced androgen receptor
(AR) activation in a stably transfected breast
cancer cell line by 55 and 60%, respectively,
whereas neither DEHP nor MEHP had a sig-
nificant effect (129). This suggests that these
metabolites may contribute to the anti-andro-
genic effects of this phthalate.
In view of these findings, it is particularly
concerning that women of childbearing age
had significantly higher urinary concentrations
of MBP than women in other age groups (90).
However, other studies did not find a signifi-
cant difference between women of reproduc-
tive age (age 20–39 yr) and younger or older
females but confirmed that women of all ages
had higher urinary concentrations of MBP,
MEP, and MBzP compared with men (88,92).
The detection of MEHP and DEHP has
been reported in umbilical cord serum, sug-
gesting that human exposure to these chemi-
cals starts in utero (143). A correlation between
detectable cord serum MEHP concentrations
and lower gestational age, although not with
birth weight or Apgar scores, was also sug-
gested. However, the improbably high concen-
trations of DEHP and its monoester and the
finding of higher DEHP than MEHP levels sug-
gest that there may have been considerable
contamination of the samples; therefore, the
above findings should be considered with cau-
tion.
Fisher et al. (121) were the first to note the
many similarities between the changes on the
cellular and tissue level induced by exposure
to DBP in utero and those observed in the tes-
ticular dysgenesis syndrome in humans. This
syndrome has its origin in abnormal fetal devel-
opment of Sertoli and Leydig cells and includes
cryptorchidism and hypospadias, testicular
germ cell cancers, and disorders of sperm
production. These disorders all constitute risk
factors for each other, and their incidence is
believed to be rising, but the evidence for each
is conflicting, with the exception of testicular
germ cell cancers (144). Additionally, there is
no convincing evidence that if there is a true
decline in male reproductive health, phthalates
and/or other endocrine-disrupting chemicals
are causally related to it.
There are first indications that phthalate
exposure is related to semen quality. In adult
men, urinary MEP levels were found to be asso-
ciated with DNA damage in sperm (as mea-
sured by the comet assay), whereas MEHP,
MBzP, MBP, and monomethyl phthalate were
not (145). There was an inverse and dose-depen-
dent relation between urinary MBP concentra-
tions and sperm motility and between MBzP
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and MBP levels and sperm concentration (146).
None of the other phthalate metabolites detect-
able in at least 75% of the urine samples, (i.e.,
MEHP, monoethyl, and monomethyl phtha-
late) were significantly associated with sperm
parameters. Changes in reproductive hormone
levels were also observed, but several of them
exhibited unexpected patterns and directions
(96). For example, inhibin B is secreted by Ser-
toli cells, and because MBP disrupts Sertoli
structure and function, it was surprising that
inhibin B increased with higher MBP exposure,
whereas follicle-stimulating hormone did not
increase. Higher MBzP exposure was associ-
ated with a decrease in follicle-stimulating hor-
mone, but there was no change in inhibin B
levels.
Note that the attempts to detect associa-
tions between phthalate exposure and semen
or reproductive hormone parameters were based
on single measurements of urinary phthalate
metabolite levels. Because of the high within-
subject variability—particularly of MEHP levels
(98)—a single sample may not have accurately
reflected average exposure to MEHP and other
phthalate monoesters, and this may account
for the failure to detect an association between
them and semen quality.
DEHP is hepatocarcinogenic in rats and
mice (77,147), but the liver tumors arise from
the ability of DEHP to act as peroxisome
proliferators in rodents, a mechanism that is
not believed to be relevant to humans. Accord-
ingly, the IARC reclassified DEHP from “pos-
sible carcinogen to humans” to “non-classifiable
as to its carcinogenicity to humans” (148).
However, the US EPA classified DEHP as a
probable human carcinogen. The decision by
the IARC has been harshly criticized for alleg-
edly not giving due consideration to all of the
available scientific evidence, particularly experi-
mental and epidemiological evidence suggest-
ing that DEHP induces pancreatic tumors in
rodents and possibly humans (149,150). A recent
addition to that database is a chronic feeding
study in Sprague–Dawley rats, in which expo-
sure to DEHP at a dose of 300 mg/kg/d sig-
nificantly increased the incidence not only of
liver tumors but also that of testicular tumors
(147). Although lower doses (30 or 95 mg/kg/
d) did not significantly increase the incidence
of Leydig cell tumors, there was a significant
trend for increasing neoplasias with increasing
dose.
Organophosphate Pesticides
The term pesticide includes herbicides,
insecticides, fungicides, fumigants, rodenti-
cides, and other chemicals designed to destroy
or repel pests. According to the US EPA, their
use (in terms of active ingredient at user level)
exceeded 5 billion pounds worldwide and 1.2
billion pounds in the United States in 2000 and
2001. When chlorine/hypochlorites (2.5 billion
pounds), wood preservatives, and specialty
biocides were included, total usage in the
United States alone was almost five billion
pounds. At least 75% of this amount is used in
agriculture, and home and garden use and
commercial/industrial/government use almost
equally share the remaining 20 to 25%. Between
80 and 90% of households have reported indoor
use of pesticides (151,152). Of particular con-
cern, 70 and 85% of pregnant women from two
New York City cohorts, respectively, reported
the indoor use of pesticides during pregnancy
(153,154), and 37% employed an exterminator
(154). The use of organophosphate (OP) insecti-
cides declined from approx 131 million pounds
in 1980 to 73 million pounds in 2001, but its
percentage among total insecticides increased
from 58 to 70% in the same period. In 1999
and 2001, the two most commonly used OP
insecticide active ingredients were malathion
and chlorpyrifos, followed by diazinon and
terbufos.
Exposure to pesticides can occur via inha-
lation, dermal absorption, and ingestion. Phar-
macokinetics studies in human volunteers
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have indicated that OPs are readily absorbed
after oral administration and are quickly me-
tabolized to more polar metabolites, which are
then eliminated in urine with half-lives rang-
ing from 2 h for orally administered diazinon
to up to 27 h for chlorpyrifos (155–158). Lim-
ited absorption was observed from occluded
dermal doses, and urinary elimination half-
lives were longer than after oral administration
(9 h for diazinon, 27–30 h for chlorpyrifos)
(155,157,158). Approximately 60% of diazinon
and 70 to 93% of chlorpyrifos were recovered
as urinary metabolites (155,157,158). Only 1 to
3% of the dose was recovered for any of the OP
pesticides investigated after dermal applica-
tion (155,157,158).
Under the Food Quality Protection Act of
1996, an assessment is required for cumulative
risks from food, water, and nonoccupational
exposure resulting from all uses of OPs and
should account for exposure to multiple pesti-
cides that have a common mode of toxicologi-
cal action and end point of toxicity. The Food
Quality Protection Act further requires that
infants and children are given particular atten-
tion because their higher food and fluid intake
per body mass, different diets, and behavior
put them at risk of higher exposure. Addition-
ally, the immaturity of the detoxifying enzyme
system in small infants and the extensive growth
and development that young children undergo
renders them more vulnerable to the potential
hormonal/endocrine disrupting, neurotoxic,
immunotoxic, and/or carcinogenic effects of
OP pesticides and other environmental pollut-
ants (152,159).
Simulations incorporating measured trans-
fer efficiencies of pesticides from surfaces to
hands and food and observations of children’s
activities during eating suggest that the fre-
quent hand–food, hand–surface, and surface–
food contacts have the potential to contribute
20 to 80% of the total dietary intake of pesti-
cides in children younger than age 4 yr (160).
After broadcast application of chlorpyrifos,
air concentrations remained markedly higher
in a child’s breathing zone (0.25 m above the
floor) than in the breathing zone of a sitting
adult (1 m), even after ventilation (161). Even
on the second day after application, the dose a
child was estimated to absorb was 0.038 mg/
kg, vastly exceeding the current US EPA RfD
for infants and children (0.0003 mg/kg/d).
It has been shown that a semivolatile pesti-
cide such as chlorpyrifos can volatilize days after
its indoor application and can be adsorbed to
various surfaces (162). Children’s felt toys, in
particular, and, to a lesser extent, plastic toys
accumulated significant levels of chlorpyrifos.
For a young child exhibiting typical mouth-
ing and hand-to-mouth behavior, dermal and
nondietary oral exposure to such conditions
were estimated to constitute a dose of 64 µg/
kg/d under the most conservative absorption
assumptions and to contribute between 40 and
60% of the total dose. This greatly exceeds the
allowable daily intake of 10 µg/kg/d proposed
by the US EPA.
Risk assessment of OP pesticides requires
knowledge of the magnitude of the exposure.
Therefore, either environmental or biological
monitoring is used. In recent years, environ-
mental monitoring has yielded information on
concentrations of OP pesticides in outdoor,
indoor, and personal air; indoor dust; soil;
and foods and beverages (see Tables 8–10). All
of the measured values vary considerably, but
it is difficult to determine whether they reflect
mostly methodological differences or repre-
sent true differences in pesticide concentra-
tions. Note that many of the available studies
have focused on chlorpyrifos and diazinon.
The US EPA eliminated essentially all indoor
residential uses of these pesticides by 2002, but
they continue to be used in agriculture.
Several important findings have emerged
from these exposure assessment studies. OP
pesticides are detectable in essentially all media
analyzed, including food, indoor air, dust, and
soil near the home. Interestingly, OP pesti-
cides were not detected in duplicate beverage
samples in two studies (163,164), whereas
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Table 10
Pesticides in Duplicate Diet Samples
379 4-d Composite duplicate
Pesticides in food solid food samples from 75 96 Duplicate solid
(in µg/kg) individuals in Maryland (164) food samples Clayton (163)
% Mean P95 % Median P90
Chlorpyrifos 38.3 0.7 2.9 57 0.532 1.26
Malathion 75.2 1.8 5.9 46 <LOD/LOQ 10.22
Atrazine 0 8 <LOD/LOQ <LOD/LOQ
Diazinon 3 <LOD/LOQ <LOD/LOQ
<LOD/LOQ, below limit of detection or limit of quantification.
others reported their detection in 4 of 21
beverage samples; 4 of 9 (44%) of the samples
that included apple juice contained azinphos-
methyl (165).
Comparisons of pesticide concentrations in
dust, soil, and surface and hand wipes have
clearly indicated that exposure of agricultural
families is considerably greater than that of
nonagricultural reference families (166–170).
This higher exposure appears to result from
both take-home pathways and proximity of the
residence to farmland (167,169,170), although
the association with proximity is not a consis-
tent finding (168).
Using food consumption data from the
Nurses Health Study and the Health Profes-
sionals’ Follow-Up Study combined with the
data from the Food and Drug Administration
Total Diet Study, researchers estimated that
mean daily dietary intakes of chlorpyrifos,
diazinon, and malathion were 0.8, 0.5, and 5.5
µg/d for women and 0.9, 0.5, and 6.1 µg/d for
men, respectively (171).
From duplicate diet samples, adult dietary
chlorpyrifos and malathion exposure has been
estimated to be 0.5 and 1.3 µg/d, respectively
(164), and dietary chlorpyrifos intake in chil-
dren was estimated to be 0.263 µg/d (163).
Mean aggregate chlorpyrifos exposure from a
total of six pathways was calculated to be 1.39
µg/d (standard deviation: 2.77 µg/d); inhala-
tion made the greatest contribution (approx
85%), whereas only between 7 and 13% was
attributable to pesticide residues in solid food,
and the dermal route was negligible (172,173).
In two studies of children’s pesticide exposure,
however, solid food made the greatest contri-
bution to the cumulative intake of chlorpyrifos,
malathion, and diazinon (84,163). Interest-
ingly, despite the high contribution that food
appeared to make to aggregate chlorpyrifos
exposure in the Minnesota Children’s Pesticide
Exposure Study, there was a much stronger
correlation between urinary metabolites of this
pesticide and concentrations in personal air
than with levels in the ingested solid food
(163). Additionally, note that the estimates of
dermal absorption neglected to account for the
volatilized portion of chlorpyrifos. The finding
of a high correlation (correlation coefficient:
0.998) between chlorpyrifos in indoor air and
in the corresponding dermal wipes suggests
that this route of exposure may be important
(57).
The reported dietary pesticide intakes were
generally well within the US EPA or similar
reference values (163,165). However, it has
been noted that dietary intake estimates greatly
depend on the assumed value of nondetect
samples, with assumption of a zero value under-
estimating exposure by a factor of 10 to 60 (171).
Biomonitoring of OP pesticide exposure
most commonly involves measurement of their
urinary metabolites or, much more rarely,
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quantification of the pesticides themselves
and/or some of their metabolites in plasma
(154,174). Whereas urinary dialkylphosphate
(DAP) metabolites (Table 11) are nonspecific
because they can be derived from a wide vari-
ety of OP compounds, certain other urinary
metabolites are specific for one or two pesti-
cides (Table 12). Recall that urinary metabolites
of OP pesticides can provide only rough esti-
mates of exposure because the amount of
absorptionand the fractional excretion of spe-
cific metabolites are not really known, nor have
all the metabolites been identified. Addition-
ally, it cannot be determined whether and to
what extent urinary metabolites represent
exposure to one or more parent compounds or
direct exposure to their metabolites. Further-
more, urinary metabolite concentrations should
be corrected for dilution, but the appropriate
method is still under debate (175), particularly
because marked seasonal fluctuations in crea-
tinine levels were observed in small children
(176).
Biomonitoring of prenatal exposure involves
the measurement of pesticides and their metabo-
lites in umbilical cord blood, amniotic fluid, or
meconium. A total of eight pesticides were
detectable in 45 to 77% of maternal plasma
samples obtained at delivery and in a similar
percentage of cord plasma samples from 230
mother–infant pairs from New York City (154).
Their concentrations in maternal and cord
plasma were similar and highly correlated,
indicating the occurrence of transplacental
transfer and substantial in utero exposure (154).
A further indication for transplacental transfer
comes from the finding that the DAP metabo-
lites DEP, dimethyl phosphate, and dimethyl-
thiophosphate were detected in 10, 10, and 5%
of amniotic fluid samples, respectively (177).
Meconium consists of fetal bile secretions
along with the content of the amniotic fluid
that the fetus swallowed, representing expo-
sure from the second trimester through deliv-
ery, and is usually not excreted by the fetus
until after birth. DEP and diethylthiophos-
phate (DETP) were present in 95 and 100% of
20 meconium samples from New York new-
borns, respectively, whereas other OP metabo-
lites were detected in only one or none of the
samples (178). Similarly, the detection of
diazinon (34.3%), malathion (53%), parathion
(32%), and chlorpyrifos (11%), along with vari-
ous organochlorine (OC) compounds, has been
reported in meconium samples from infants in
the Philippines (179). Up to six or seven pesti-
cides were detected in 4 and 5% of the samples,
respectively.
Some investigators detected an association
between reported indoor residential pesticide
use and urinary concentrations of specific pes-
ticide metabolites(180), but this association
was not detected in several other studies of
children and adults (153,181,182). Reported
pesticide use in the garden is also not consis-
tently associated with urinary DAP levels
(180,182). A significant correlation was reported
between levels of chlorpyrifos, diazinon, and
the carbamate propoxur in personal air and the
concentrations of these insecticides or their me-
tabolites in plasma obtained within a month of
the personal monitoring, but there was no cor-
relation in plasma obtained at later time-points
(154). Because of the relatively short half-lives
of these pesticides, the relevance of these cor-
relations is difficult to evaluate without further
information about the regularity or chronicity
with which the women were exposed to these
pesticides.
Several studies in which urinary pesticide
metabolite levels were measured have con-
firmed the findings of environmental monitor-
ing studies that farm children are exposed to
higher levels of OP pesticides compared with
children from nonagricultural reference fami-
lies (168,169), particularly during periods of
pesticide application (183). In one of these stud-
ies, azinphosmethyl was the pesticide detected
with the highest frequency and at the highest
concentrations in house dust and was signifi-
cantly correlated with dimethyl DAP metabo-
lites in urine (168). Only the study that detected
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an association between house dust levels of
azinphosmethyl and phosmet and proximity to
farmland also found higher dimethyl DAP lev-
els in children living near treated orchards
compared to those living at a greater distance
(169). In the same group of subjects, however,
urinary levels of the major chlorpyrifos metabo-
lite, 3,5,6-trichloro-2-pyridinol (TCPy) were not
significantly different between children from
agricultural and nonagricultural families and
did not reflect distance from orchards, although
chlorpyrifos was present at higher concentra-
tions in house dust of farming families and was
increased with increasing distance from pesti-
cide-treated areas (167).
Although studies of exposure to individual
pesticides, even those considering aggregate
exposure, have generally found the estimated
exposure levels to be well below the RfD (163),
there is increasing evidence from biological
monitoring studies that exposure to OP pesti-
cides overall may exceed reference doses in a
substantial number of subjects from both agri-
cultural and nonagricultural areas.
Calculations of exposure using urinary
DAP metabolites are difficult because these
metabolites can originate from a large variety
of OP pesticides with highly different chronic
toxicity and RfD values. In 2- to 5-yr-old children
from urban and suburban areas of Seattle, the
percentage of exposure estimates exceeding US
EPA guidelines ranged between 0 and 100%,
depending on which pesticide was assumed to
be responsible for the exposure (184). When
pesticides commonly applied in an agricultural
community in Washington were used to cal-
culate the absorbed daily dose in children age
6 yr or younger, 9 to 56% of children from ag-
ricultural families and 0 to 44% of reference chil-
dren exceeded the EPA RfD for azinphosmethyl
and phosmet (3 and 11 µg/kg/d, respectively)
during the spray season (185). Similar calcula-
tions for the same age groups of children from
Yuma County, Arizona, indicated that the
highest daily dose values were 61 to 385 times
higher than the EPA RfD (176).
In a study of pregnant women in the Sali-
nas Valley in California, the estimated exposure
to OP pesticides exceeded the oral benchmark
dose10 of the US EPA in 0 to 36% of the women,
depending on the index chemical on which the
estimate was based and exceeded the bench-
mark dose for 10% response in approx 15% of
women regardless of the parent compound
(186). The benchmark doses for 10% response
are doses expected to result in a 10% reduction
in brain cholinesterase activity in rats.
Notably, there is evidence from urinary
DAP assessments that suggests that consump-
tion of a predominantly organic diet can greatly
reduce dietary exposure to OP pesticides as
well as the associated risk (184). However,
daily consumption of a single meal prepared
with organically grown produce was not suffi-
cient to significantly influence urinary levels of
DAP metabolites (180).
Associated Health Problems
OP pesticides and carbamates inhibit ace-
tylcholinesterase (AChE). Because AChE inacti-
vates acetylcholine (ACh) at neuronal junctions,
its inhibition results in ACh accumulation and
continued neurotransmission. Because the
autonomic, the somatic, and the central ner-
vous systems all use ACh, the symptoms of
OP-mediated AChE inhibition are manifold
and include dizziness, headache, confusion,
convulsions, blurred vision, respiratory dis-
tress, bradycardia and hypotension, fatigue,
weakness, ataxia, muscle cramps, and increased
lacrimation and salivation. Although the effects
of environmental OP exposure are milder, they
can resemble those of acute poisoning and,
incidentally, include some well-known SBS
symptoms, such as tearing eyes, chest pres-
sure/tightness, and feeling dazed (187).
Numerous animal studies have documented
the developmental neurotoxicity of gestational
or early postnatal exposure to OP pesticides at
relatively low levels that did not result in overt
systemic toxicity and inhibited cholinesterase
to a minor extent (approx 20%) in the dam
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(159). Such exposure resulted in impairments
in maze performance, locomotion, coordina-
tion and balance, righting reflexes, and cliff
avoidance. The molecular and cellular changes
in the fetal or newborn brain that could account
for these effects include inhibition of brain
AChE and choline acetyltransferase activity
(188–190), alteration of muscarinic receptor
function via inhibition of ligand binding and
permanent reduction in the density of muscar-
inic cholinergic receptors (188,189,191,192),
altered synaptic development and function
that can persist into adulthood (193), decreased
expression and activity of multiple compo-
nents of the adenylyl cyclase cascade (194),
impaired DNA (195) and RNA synthesis (196),
and reduced cellularity and brain weight in off-
spring. Most of these studies were performed
using chlorpyrifos, but similar effects and
mechanisms were observed with other OP pes-
ticides (159) as well as two different pyre-
throids (191).
Few studies have addressed possible
 neurodevelopmental effects of prenatal OP
exposure in humans. Recently, the association
between prenatal OP pesticide exposure and
neonatal neurodevelopment as assessed by the
Brazelton Neonatal Behavioral Assessment
Scale was investigated in 381 full-term infants
in the CHAMACOS project. Table 11 includes
maternal DAP metabolite levels during preg-
nancy in this cohort of women, which con-
tained a substantial portion of agricultural
workers from the Salinas Valley and other
women with rather high environmental expo-
sure to pesticides because of their heavy use in
this agricultural center. Total, dimethyl, and
diethyl DAP in urine were all significantly as-
sociated with an increased number of abnor-
mal reflexes (failure to respond or hypoactive
response) and the proportion of neonates with
more than three abnormal reflexes (197). Inter-
estingly, the association differed depending on
the age at which the Brazelton Neonatal Behav-
ioral Assessment Scale was administered. The
association was negative in neonates examined
after age 3 d but was unexpectedly positive in
infants assessed within the first 3 d of life (n =
197).
An ecological study of 4- to 5-yr-old Yaqui
children in Mexico demonstrated decreases in
stamina, hand–eye coordination, and recall
and an almost complete inability to draw a per-
son in children living in an agricultural valley
who were exposed to multiple pesticides com-
pared to children from families living in the
foothills who were employed in ranching (198).
Notably, the two groups shared genetic, cul-
tural, and social traits and differed mostly in
type of parental employment and the use of
pesticides and chemical fertilizers.
Several other cohorts have been established
for the investigation of the effects of in utero
OP pesticide exposure on pregnancy and
neurodevelopmental outcomes. Only preg-
nancy outcomes have been reported for these
cohorts as well as for women of the CHAMACOS
project. In the CHAMACOS cohort, DAP me-
tabolites were associated with a significant
increase in head circumference and a margin-
ally significant increase in birth length (199).
Only dimethyl phosphate, and not DEP, metabo-
lites and cord cholinesterase activity were signifi-
cantly associated with decreased length of
gestational duration. In marked contrast, in a
cohort of African-American and Dominican
women from New York, cord blood concentra-
tions of chlorpyrifos were a significant inde-
pendent predictor of decreased birth weight
and birth length (200). Ethnic-specific regres-
sions indicated that the effect on birth weight
was statistically significant only among Afri-
can-American women, whereas the effect on
birth length was significant only in Dominican
women. An extension of this study confirmed
the significant association between cord plasma
chlorpyrifos and diazinon levels and decreased
birth weight and length in a somewhat larger
cohort, but it was unable to detect an associa-
tion with insecticide concentrations in maternal
personal air during pregnancy (201). Notably,
although the associations between cord plasma
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concentrations of chlorpyrifos and diazinon
were highly significant in children born before
the US EPA started to phase out residential use
of these pesticides, they were no longer detected
in children born after. However, only cord
plasma chlorpyrifos, but not diazinon, levels
were significantly decreased in the relevant
period.
In a different cohort of pregnant women in
New York, no association was detected between
self-reported pesticide use during pregnancy,
urinary levels of TCPy, or pyrethroid metabo-
lites obtained during the third trimester and
birth weight, length, head circumference, or
gestational age (202). However, when mater-
nal activity of the phase-II detoxifying enzyme
paraoxonase 1 activity was accounted for,
maternal urinary chlorpyrifos metabolite
levels were associated with a small, but signifi-
cant, decrease in head circumference. Most of
the enzymes involved in the metabolism, acti-
vation, and detoxification of OP pesticides and
other chemicals discussed here exhibit poly-
morphisms that greatly influence enzyme activ-
ity. This study represents one of the rare
examples where at least one of these polymor-
phisms was accounted for.
Notably, urinary levels of pesticide metabo-
lites are highly variable, and measurements
obtained at three different time-points show
significant within-person variability (163,186).
Therefore, one or two spot-urine samples are
unlikely to provide a reliable measure of pesti-
cide exposure throughout pregnancy. This
may partially explain the inconsistent findings
regarding birth outcomes in the aforemen-
tioned studies. Whether cord plasma or meco-
nium concentrations constitute a more reliable
measure remains to be established.
Other Health Effects of OP Pesticides
Chronic exposure of rats to the pesticide
rotenone has been found to constitute an animal
model of Parkinson’s disease that reproduces the
typical biochemical, molecular, anatomical,
and behavioral findings in Parkinson’s disease
(203). These include binding to complex I in the
brain, selective nigrostriatal dopaminergic
degeneration with relative sparing of the
dopaminergic fibers in medial aspects of
striatum, cytoplasmic inclusions containing
ubiquitin and α-synuclein resembling the
Lewy bodies associated with Parkinson’s dis-
ease, and hypokinesia and rigidity. Notably,
rotenone is a “natural” plant-derived com-
pound that even organic farmers use on veg-
etable crops.
Several epidemiological studies have sug-
gested an association between agricultural
work, which usually includes pesticide expo-
sure, or pesticide exposure per se and idio-
pathic Parkinson’s disease (204–208), although
others have found only suggestive evidence
for such an association (209) or have found no
association (210).
There is increasing evidence that occupa-
tional exposure to certain pesticides increases
the risk of several cancers, including cancers of
the brain (211) and lungs (211–213), acute
myeloid leukemia (211), and possibly mul-
tiple myeloma (214). Children may be particu-
larly sensitive to the carcinogenic effects of
pesticides, as suggested by numerous reports of
associations between residential pesticide expo-
sure and childhood cancers—particularly brain
cancer and leukemia but also Wilm’s tumor,
Ewing’s sarcoma, and germ cell tumors (215,
216).
Because cholinergic nerves in the vagi pro-
vide the major neural control of airway tone
and reactivity, it seems plausible that OPs
could induce airway hyperreactivity and
asthma (159). Seven days after a single subcu-
taneous injection of 70 mg/kg of chlorpyrifos,
vagally induced bronchoconstriction was found
to be potentiated in guinea pigs in the absence
of AChE inhibition (217). This effect was accom-
panied by decreased M2 muscarinic receptor
function, whereas M3 receptor function was not
affected. Similar results were obtained 24 h after
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administration of 1 or 10 mg/kg of parathion
and 0.75 or 75 mg/kg of diazinon, although
only the higher doses inhibited AChE (218).
Intraperitoneal administration of parathion
to guinea pigs increased lung resistance and
mucus secretion and induced pulmonary edema
(219). These broncho-obstructive effects were
demonstrated to depend on the biotransforma-
tion of parathion by P450 enzymes. Even doses
that did not increase lung resistance were able
to induce airway hyperresponsiveness not
only to ACh but also to histamine. The latter
was prevented by atropine, suggesting the
involvement of a cholinergic mechanism.
In the Agricultural Health Study, data col-
lected on more than 20,000 farmers indicated
that use of the OPs malathion and chlorpyrifos
dose-dependently increased the risk of wheeze,
and parathion also carried an elevated OR
(220). It remains to be established whether OP
pesticides at environmental exposure levels
increase the risk of asthma and asthma-like
symptoms.
Organochlorines
OCs comprise a diverse group of synthetic
chemicals that include not only pesticides but
polychlorinated biphenyls (PCBs), polybromi-
nated biphenyls, polychlorinated dibenzofurans
(PCDFs), and polychlorinated dibenzodioxins
(PCDDs). OC pesticides include 1,1,1-trichloro-
2,2-bis(p-chlorophenyl)ethane (DDT); lindane
and other hexachlorocyclohexanes; cyclodienes
such as dieldrin, chlordane, and heptachlor;
and hexachlorobenzene. Many OCs—particu-
larly the more heavily chlorinated ones—resist
biotic and abiotic degradation and are lipo-
philic; therefore, they not only bioaccumulate in
all parts of the environment, but are biocon-
centrated from one trophic level to the next.
PCDDs and PCDFs are tricyclic aromatic
compounds. Because they can be substituted
with between one and eight chlorine atoms,
there are potentially 75 different PCDD and
135 PCDF congeners (isomers with similar
halogen substitution patterns). However, the
actual number present in biotic samples is
much lower, and mainly 2,3,7,8-substituted
congeners are detected. The most toxic congener
is 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD),
often referred to simply as “dioxin,” whereas
the PCDDs are called dioxins.
There are 209 possible PCB congeners,
which differ in the degree of chlorination and
the position of the chlorine atom; however,
depending on the species and its trophic level,
only between 50 and 150 congeners are detect-
able in biotic samples (221). Whereas PCDDs
and PCDFs have rigid planar structures, the
two rings of PCB molecules are joined by a
single carbon–carbon bond, thus allowing axial
rotation of the benzene rings. This freedom is
restricted by the number and positions of the
chlorine substituents and decreases from non-
ortho via mono-ortho to di-, tri-, and tetra-
ortho PCBs. Planar PCBs exhibit the greatest
resemblance to the dioxins.
Whereas PCBs and polybrominated biphe-
nyls were purposely produced for use as dielec-
tric fluid in transformers and capacitors,
hydraulic fluid, plasticizers, and fire retar-
dants, PCDD/Fs arise as byproducts of ther-
mal and industrial processes, particularly via
incineration of municipal and hazardous
waste. PCBs were produced in the United
States from the 1920s until they were banned
in 1977, with peak production occurring dur-
ing the 1960s and 1970s. Historical global pro-
duction of PCBs is conservatively estimated at
1.3 million tons, which were used almost exclu-
sively in the Northern hemisphere (222). Emis-
sions (i.e., releases into the environment) of
PCBs were estimated to be in the range of 440
and 92,000 tons (223), and other data strongly
have suggested that actual emissions were
closer to the upper estimate (224,225). The envi-
ronmental residence times of two of the major
PCB congeners, PCBs 153 and 180, were recently
estimated to be 110 and 70 yr, respectively (225),
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suggesting that although the production of
PCBs was halted approx 30 yr ago, exposure
will continue for decades, if not centuries.
Exposure Routes
Because persistent OCs are lipophilic, re-
sist metabolism and biodegradation, and
bioaccumulate to similar extents in various
biota, humans are simultaneously exposed to
complex mixtures of these compounds. How-
ever, the precise nature of the mixture depends
on various factors such as solubility, volatility,
and rates of degradation as well as dietary and
other lifestyle factors and geographic location.
For the purposes of risk assessment and regu-
latory action, the concept of toxic equivalency
factors (TEFs; i.e., potency factors relative to
TCDD) has been developed (226). It is based
on evidence that PCDDs, PCDFs, and certain
PCBs exert their toxicity via binding to the aryl
hydrocarbon receptor and subsequent induc-
tion of gene expression, particularly of various
cytochrome P450 isozymes. The TEF concept
assumes that the combined effects of these OCs
can be predicted by a model of concentration
addition. TEF values can then be used to calcu-
late toxic equivalent (TEQ) concentrations by
multiplying the concentrations of each PCDD,
PCDF, or PCB by its TEF. Commonly, either
the World Health Organization (WHO) TEQs
or the international TEQs (I-TEQs) developed
by the NATO are used.
Inhalation of airborne OCs, stemming mostly
from municipal and industrial incinerators and
open burning of household trash, and dermal
exposure make comparatively minor contribu-
tions to exposure. More than 90% of current
exposure to background levels of PCBs (diox-
ins and dibenzofurans) and DDT and its metabo-
lite dichlorophenyl dichloroethylene (DDE) is
believed to come from the dietary intake of
contaminated foods—particularly dairy prod-
ucts, meat, and fish (227,228). Fish can contrib-
ute 75% or more of total PCDD/F and PCB
TEQ ingestion in countries with high fish con-
sumption (229), and in several studies, intake
of fish—particularly from highly contaminated
waters like the Great Lakes or the Baltic sea—
has shown a significant association with serum
concentrations of PCBs and their metabolites
and PCDD/Fs (228,230–234).
Notably, the traditional diet of many Arctic
populations includes substantial amounts of
marine foods, including sea mammals. Although
OCs have been produced and used primarily in
the lower and middle latitudes of the Northern
hemisphere, long-range transport via the pre-
dominantly northward flow of rivers and
ocean and atmospheric currents results in high
exposure levels in the Arctic (235). Because of
their lipophilicity and resistance to biodegra-
dation, many OCs bioaccumulate in fatty tis-
sues and are biomagnified in the aquatic food
webs. Sea mammals are predators at the top of
their food chains and contain very high levels
of OCs. Their consumption is associated with
concentrations of PCBs and other OCs in serum,
breast milk, and adipose tissue samples obtained
from various Inuit populations that are up to
fivefold higher than in other North American
or European populations (236–238).
In the United States, daily dietary intake of
dioxin TEQs in the early 1990s was estimated
to be 0.3 to 3.0 pg/kg body weight TEQs for an
adult who weighed 65 kg (239). Estimates in
eight European countries during the 1990s
(assessed by various methods) varied between
65 pg I-TEQ/d in the Netherlands and 210 pg
I-TEQ/d in Spain, which is equivalent to 1 to
3 pg I-TEQ/kg body weight/d assuming a
body weight of 70 kg (240). A more recent mar-
ket basket study conducted in Finland on almost
4000 samples representing 228 food items, com-
bined with results of a 1997 dietary survey,
produced a similar estimate of 115 pg WHO-
TEQ/d, or 1.5 pg WHO-TEQ/kg body weight
using an average weight of 76 kg (229). Up to
threefold higher values for mean daily PCB
and dioxin intake estimates have been reported
for children (241,242). In most of the countries,
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the contributions of dioxins and dioxin-like
PCBs to total TEQs were roughly equal, vary-
ing between approx 40 and 60%. Together, these
data indicate that the daily intake of dioxin
TEQs of many Europeans exceeded and prob-
ably still exceeds the TDI of 1 to 4 pg/kg/d rec-
ommended by the WHO (243). TDI or acceptable
daily intake values indicate the amount of a
chemical a person can be exposed to on a daily
basis over his or her lifetime without suffering
deleterious effects.
There are numerous indications from stud-
ies of adipose, serum, and breast milk levels
showing that exposure to OCs has been gener-
ally declining in North America and Europe
since their peak production in the late 1960s
and early 1970s (244–250). The most consistent
decline is observed in the concentrations of
DDT and its metabolites, whereas the tempo-
ral development of PCB and PCDD/F levels is
somewhat more erratic. In Europe, concentra-
tions of PCDD/Fs and PCBs have been decreas-
ing in many food stuffs, and there are indications
that changes in consumer dietary patterns—
particularly reduced fat consumption—have
also contributed to a decrease in OC intake
(240). Note that DDT is still utilized for vector
control, and the use of many OC compounds
continued for much longer periods in many
other countries around the world than in the
United States and Europe. Therefore, the body
burden of certain OCs is still very high in numer-
ous populations (251,252). Additionally, major
contamination incidents continue to occur
because of inappropriate waste disposal, and
these add considerably to the body burden of
the affected populations in countries where OC
levels are generally declining (253).
Although levels of OCs in breast milk have
been decreasing since the earliest measure-
ments in the 1980s (248,254,255), they still fre-
quently result in infant exposures that are up
to two orders of magnitude higher than TDI
values. Such values are based on lifetime intakes
and are not intended to apply to the relatively
short nursing period. On the other hand, as
previously discussed, infants are likely to be
considerably more susceptible to the various
toxic effects of environmental pollutants, in-
cluding OC compounds.
It has been estimated that nursing contrib-
utes 6 to 12% of cumulative TEQ intake until
the age of 25 yr (241). For children and adoles-
cents up to age 17 yr, duration of breastfeeding
alone or in combination with PCB concentra-
tions in breast milk or maternal plasma lipids
predicted serum PCB concentrations (227,244,
256–258). Inclusion of an index of body fat
mass was found to further improve the predic-
tive ability of this model (259).
For almost 2000 participants of NHANES
III, serum concentrations were determined
for 25 PCB congeners (260). For all conge-
ners, including some of the most commonly
detected, the 50th percentile was lower than
the limit of detection (LOD). For a surprising
number of congeners, even the 95th percentile
was lower than the LOD. For PCBs 118, 138,
153, and 180, the 75th percentile values were
13.1, lower than LOD, lower than LOD, and
37.4 ng/g of lipid, respectively. Similar data
from other studies are not directly comparable
because they were not population-based, were
obtained by different analytical methods, and
were not always on blood lipid base. Nonethe-
less, it is striking that some of these studies
detected PCBs 138 and 153 in a high percent-
age of subjects. For example, despite similar
detection limits as those reported in the Cen-
ters for Disease Control study, PCBs 138 and
153 were detected in 93 and 97%, respectively,
of umbilical cord plasma samples obtained
from neonates born to Canadian women living
in southern Québec and exposed to background
levels of PCB (261). The geometric mean val-
ues were 12.7 and 16.9 ng/g of plasma lipids,
respectively. In blood samples from German
schoolchildren obtained between 1996 and
2003, all 5th percentile values for PCBs 138, 153,
and 180 were above the detection limit (244).
Median concentrations in the most recent
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samples (2002/2003) were 0.01, 0.03, and 0.01
µg/L for PCBs 138, 153, and 180, respectively.
Significant correlations between maternal
and cord serum concentrations of PCBs and
other OC compounds suggest the occurrence of
transplacental transfer (261–263), and neonatal
levels of PCBs have been found to increase with
length of gestation in full-term neonates born
after 38 to 42 wk of gestation (264). The detec-
tion of OCs in amniotic fluid and meconium
samples has also been reported (179,265), fur-
ther confirming that OC exposure starts in utero.
Absorption and Elimination
The limited human data available indicate
almost complete absorption of lower chlori-
nated PCB and PCDD/F congeners and some-
what lesser, but still substantial, absorption of
the higher chlorinated congeners (266–268).
There is still uncertainty about the extent of
dermal absorption, which appears to depend
not only on the degree of chlorination (269) but
also on the matrix in which PCBs are applied
(270) and on the method used to estimate absorp-
tion (271). One of the most common methods,
fecal and/or urinary excretion of label, may
considerably underestimate dermal absorp-
tion, as indicated by the finding that when tis-
sue distribution was accounted for in a mass
balance study in pigs, absolute dermal absorp-
tion of a single PCB congener was found to be
22%, whereas the urinary and fecal excretion
methods would have indicated absorption of
only 8 to 10% (271).
After initial distribution to highly perfused
tissues such as liver and muscle, PCBs are then
redistributed to adipose tissue and skin, which
serve as long-term storage sites (272). The pri-
mary sites to which more than 95% of the body
burden of PCDD/Fs distributes are the liver
and adipose tissues, including blood lipids and
the adipose tissue of muscles and skin (273,274).
The major metabolites of PCBs are methyl
sulfones and polychlorobiphenylols (OH-PCBs).
Although the hydroxylation of lipophilic sub-
stances renders them more hydrophilic and
generally facilitates their excretion, there are
indications that some OH-PCBs are selectively
retained, mainly by binding to plasma proteins
such as albumin and the thyroid hormone
transport protein, transthyretin (275). In vitro,
the affinity of certain OH-PCBs for transthyretin
has been shown to be up to four times stronger
than that of thyroxine (T4) (276). Although at
least 38 OH-PCBs have been identified in human
blood plasma (277), five hydroxylated metabo-
lites constitute the vast majority of OH-PCBs
in plasma (231,275,278–280). The ratio of total
OH-PCBs to total PCBs is generally in the
range of 0.1 to 0.3, with declining ratios at
higher total PCB concentrations (278–280).
Estimated half-lives range from a few years
to 30 yr or more for the more persistent PCBs
(281), from 7 to 8 yr for TCDD (282,283), from 3
to more than 15 yr for other PCDDs, and from
3 to almost 20 yr for PCDFs (282); half-lives are
approx 7 yr for DDT (284) and approx 10 yr
for DDE (285). Notably, elimination rates for
TCDD appear to depend on age (286) and body
fat (283) and are believed to slow with decreas-
ing body burden (287–289). OCs are primarily
excreted in the bile (272,290). Lactation can also
represent a major route of excretion. The high
levels of OCs found in breast milk indicate that
OCs are mobilized from adipose tissue dur-
ing lactation, and significant decreases in the
maternal body burden of PCDD/Fs and PCBs
with simultaneous accumulation in their infants
has been observed, particularly following the
first delivery (291,292).
Health Effects of OC Compounds
Much of the knowledge of the health effects
of OCs comes from highly exposed occupa-
tional cohorts and from Air Force personnel
involved in the spraying of Agent Orange in
Vietnam. Additionally, there are three cohorts
that experienced high levels of environmental
exposure. Because of an industrial accident in
Seveso, Italy, the air and soil from surrounding
areas were contaminated mostly with TCDD.
Two industrial accidents in Japan and Taiwan
CRIAI_31_Final Appl 7/17/06, 1:47 PM38
Airborne Environmental Injuries and Human Health 39
Clinical Reviews in Allergy & Immunology Volume 31, 2006
resulted in the contamination of cooking oil,
primarily with PCBs and PCDFs. The resulting
symptoms were referred to as Yusho in Japan
and Yu-Cheng in Taiwan (meaning “oil dis-
ease”). Table 13 provides brief descriptions of
these cohorts.
There should be a note of caution in inter-
preting epidemiological studies that analyze
associations between exposures to OC com-
pounds and various health effects. Gener-
ally, either PCBs or PCDD/Fs, but not both
groups of compounds, have been measured in
these studies. However, humans are invariably
exposed to mixtures of these and other OC
compounds, and the contributions of the indi-
vidual components of the mixture to the effect
under investigation are unknown. Addition-
ally, several studies of OC tissue levels in North
America and Europe found modest-to-strong
correlations not only between total PCBs and
PCDD/Fs but also among and between indi-
vidual PCBs and PCDD/Fs (254,259,293–297).
Together, these factors can result in not only
considerable confounding but in misclassifi-
cations of the observed effects (294). This is
most clearly illustrated by the fact that some
PCB congeners are dioxin-like and, similar to
dioxins, exert most of their effects through the
Ah receptor, whereas others act as Ah receptor
antagonists. Developmental neurotoxicities
represent an example of an effect to which both
Ah receptor-mediated mechanisms and mecha-
nisms that are not Ah receptor-mediated are
likely to contribute.
On the other hand, the strong correlation
(r > 0.9) between some individual PCB conge-
ners, such as PCB 153 or PCB 138, and total
PCBs allows use of only a few PCB congeners
as a measure of total PCB exposure. In many
recent epidemiological studies, PCBs 138, 153,
180, and, frequently, PCB 118 were used to es-
timate total PCB burden (298,299).
In 1997, the IARC classified TCDD as a
group 1 human carcinogen but considered
other PCDDs and PCDFs as not classifiable
regarding their carcinogenicity in humans
(300,301). DDE and certain PCBs have estro-
genic activity in vitro and in vivo, and an asso-
ciation between higher blood levels of DDE
and PCBs and breast cancer has been sug-
gested in some case–control studies, but this
has not been confirmed in most of the recent
studies (302).
There is increasing, although not entirely
consistent, evidence from occupationally and
otherwise highly exposed cohorts that TCDD
and possibly other PCDD/Fs are associated
with increased mortality from ischemic heart
disease (303–305). Even at background levels
of exposure, TCDD was found to increase the
risk of type 2 diabetes (303,306,307), and this
increase was not associated with the TCDD
elimination rate (308). Again, the data are not
entirely consistent (309,310). An association
has also been suggested between PCB expo-
sure and diabetes (mostly type 1) (311).
Birth Outcomes
In women who gave birth between 1959
and 1966, the OR of preterm birth was signifi-
cantly increased, with increasing concentra-
tions of DDE in maternal serum (284,312). A
less consistent, but significant, increase in the
OR of being small for gestational age was also
observed (312). The reduction in birth weight
of children born to mothers who frequently
consumed more Great Lakes sport-caught fish
compared to children of mothers who rarely
consumed contaminated fish was also associ-
ated with higher maternal serum DDE levels
but not PCB levels (313). However, such effects
of DDE have not been observed in studies of
more recent cohorts, suggesting that they may
no longer occur at current exposure levels
(238,314,315).
There were signs of intrauterine growth
retardation in children of Yusho and Yu-Cheng
mothers (316,317), but it is unclear whether this
resulted from the PCBs, PCDFs, and/or the
thermal degradation products of PCBs. An asso-
ciation between exposure to background levels
of PCBs and birth weight or gestational age has
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not been seen consistently (238,284,318–321).
There is also no strong evidence for a negative
effect of PCDDs and PCDFs on birth outcomes
(321,322).
In the Seveso cohort, the sex ratio (male-to-
female) in the children born after the accident
became lower with increasing paternal expo-
sure to TCDD, as assessed in serum samples
collected in 1976 and 1977 (323,324). This was
particularly obvious in fathers exposed before
the age of 19 yr (sex ratio: 0.38). The exposure
levels of the mothers were not associated with
any changes in sex ratio. Almost identical results
were recently reported in workers from a Rus-
sian pesticide-producing plant exposed to high
levels of dioxin (325). Conversely, no signifi-
cant differences in the sex ratio were observed
in the Yusho and Yu-Cheng incidents in Japan
and Taiwan (326,327) or in children born to
veterans of Operation Ranch Hand who were
exposed to Agent Orange (328).
Neurodevelopmental Effects
The possible neurodevelopmental toxicities
of PCBs and PCDD/Fs are one of the major
concerns regarding environmental background
exposure to OCs and are the focus of much
ongoing research. Gestational exposure of
rodents and monkeys to PCBs is consistently
found to have negative effects on learning as
well as locomotor activity and function (221).
In the Taiwanese Yu-Cheng incident, exposed
mothers reported a delay in 32 of 33 develop-
mental milestones in their children who were
born up to 7 yr following the poisoning (317).
The exposed children also scored consistently
lower than controls on several formal cognitive
and behavioral tests, with the exception of the
verbal IQ on the Wechsler Intelligence Scale for
Children (317,329). Similar levels of exposure
to PCBs that were not contaminated by PCDFs
were associated with markedly less toxicity,
thus implicating the PCDFs or other thermal
breakdown products present in the contami-
nated cooking oil in the observed neurodevel-
opmental effects (317). Children in the Japanese
rice oil poisoning were not formally tested but
were reported to exhibit hypotony, hyperactiv-
ity, and altered latencies and amplitudes of
auditory evoked potentials and were reported
to have lower mean intelligence quotients
(221).
Table 14 summarizes the associations of
neurodevelopmental outcomes in infants and
children with the PCB exposure levels of their
mothers. Several methodological aspects greatly
hamper comparison of the results. One of the
difficulties is that different specimens (mater-
nal serum or plasma, maternal milk, cord serum
plasma) were used for exposure assessment,
and the results were expressed per wet-weight
or per gram lipid of the respective tissues.
Additionally, the earlier studies measured
PCBs by the packed column gas chromatogra-
phy method and did not quantitate individual
congeners, whereas in more recent studies,
various combinations of individual congeners
were measured. Longnecker et al. (330) used a
variety of approaches to re-express the reported
PCB concentrations as median PCB 153 levels
in nanogram per gram of lipid in maternal serum
for six of these cohorts (257,299,314,331,332) as
well as for four other cohorts for which data
on neurological testing are not yet available.
These calculated PCB 153 concentrations are
included in Table 14. The use of PCB 153 for
this purpose is appropriate because PCB 153 is
highly correlated with total PCBs. Although
substantial uncertainty arises from the assump-
tions that were made to convert packed-column
into high-resolution results and milk into serum
levels, the authors felt that the primary findings
were not be substantially altered. These pri-
mary findings demonstrated substantial over-
lap in the distribution of exposure in the
majority of studies, but the median exposure
in the Faroe Islands was fourfold higher than
the overall median.
As summarized in Table 14, the overall
results of these studies indicate that prenatal
PCB exposure is associated with subtle, but
significant, delays in the neurodevelopment of
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infants and children. Despite the much greater
transfer of OCs from the mother to the infant
via breast milk, most studies have not revealed
any significant associations between postnatal
exposure via breastfeeding and neurodevel-
opmental outcomes (331,333–335). The excep-
tions are discussed here.
The strongest and most persistent adverse
effects were observed in the Michigan cohort,
which included mothers who frequently con-
sumed PCB-contaminated sports-caught fish
from Lake Michigan (331,333,336–338). Nota-
bly, the early developmental findings in the
Michigan cohort have essentially been replicated
in the Oswego cohort, which also included moth-
ers who had consumed substantial amounts of
sport-caught fish from Lake Ontario (334,339–
341). The only difference was that studies of the
Michigan cohort indicated a weak, but statisti-
cally significant, association between maternal
fish consumption and performance on the
Fagan test (preference for novelty), whereas
such an association was not found in the Oswego
cohort (334). However, the effect size in the
Oswego cohort was considerably smaller than
reported for the Lake Michigan cohort (2.1 and
1.4% at 6 and 12 mo, respectively, vs 10.4% at
7 mo), which might be attributable to the
lower levels of PCB and other contaminants in
the Lake Ontario mothers compared with the
Oswego mothers. However, note that the esti-
mated PCB 153 concentrations in the Michigan
cohort were similar to those observed in the
Dutch cohort and were somewhat lower com-
pared with the German cohort (330). In the
German cohort, no effect of prenatal PCB expo-
sure was found using either the Fagan test or
Bayley Scales of Infant Development (BSID)
(257,298). However, early postnatal PCB expo-
sure (PCBs in early breast milk samples) showed
a significant negative association with the
Bayley II mental, but not psychomotor, devel-
opmental index at age 7 mo (298). Negative
associations between the PCB concentration
in milk and mental and motor development (as
assessed with the BSID) were only of border-
line significance at age 7 and 18 mo but became
highly significant in 30-mo-old children in that
cohort (257). Mental development continued to
be negatively affected by lactational PCB expo-
sure at age 42 mo (as assessed by the Kaufmann
Assessment Battery for Children). In the
Rotterdam cohort, postnatal PCB and dioxin
exposure via breastfeeding was also negatively
correlated with BSID scores at age 7 mo (263).
Conversely to the German findings, this study
also demonstrated an effect from prenatal expo-
sure. In further contrast to the results from the
German cohort, it was the psychomotor, but
not the mental, development index that was
significantly decreased, and the associations
were no longer significant at age 18 mo.
Lower full-scale and verbal IQ scores were
still associated with a composite measure of
prenatal PCB exposure in 11-yr-old children
from the Lake Michigan cohort (331). No other
cohort has been followed for such an extended
period, but in another study, significant effects
of prenatal PCB exposure were no longer ap-
parent in children past age 3 yr (342). Others
found that the children with the highest prena-
tal exposure caught up to the performance
level of the least exposed children by age 54 mo
(341) or that in utero PCB and dioxin exposure
continued to significantly affect cognitive and
motor abilities past age 6 yr only in those with
suboptimal home environments (343). The lat-
ter finding suggests that more optimal intellec-
tual stimulation can counteract the effects of
prenatal PCB exposure. Other investigations
confirmed that the home environment (HOME
score) had a positive influence on mental devel-
opment that was greater overall than the nega-
tive effect of neonatal PCB exposure (257).
There are also indications that breastfeeding
has a positive influence on mental and psycho-
motor development and can counteract some
of the negative effects of PCB exposure (263).
Because the majority of studies indicated that
prenatal rather than postnatal exposure was
CRIAI_31_Final Appl 7/17/06, 1:47 PM46
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associated with neurodevelopmental param-
eters, a WHO working group did not find the
evidence sufficient to change the WHO recom-
mendation to support breastfeeding (221).
In the Dutch cohort from Rotterdam and
Groningen (see also Table 14), exposure to both
PCBs and dioxins was assessed (344). Because
of the requirement for rather large sample vol-
umes, PCDD/Fs could not be measured in
cord blood, but they were determined in a 24-h
breast milk sample obtained during the second
week after birth. Their concentrations were not
associated with any measure of neurological
condition up to age 42 mo (318,344–346). In
another brief publication on this cohort, it was
reported that the mean sum of all TEQs from
dioxins and dioxin-like PCBs (total PCB-dioxin
TEQ) was actually higher in neurologically
normal newborns compared with the 24 chil-
dren classified as neurologically slightly or defi-
nitely abnormal (347). However, at age 3 mo,
total PCB–dioxin TEQs tended to be associated
with a reduction in the psychomotor develop-
mental index (263). Additionally, postnatal to-
tal PCB–dioxin TEQ exposure (accounting for
the duration of breastfeeding) was associated
with significantly lower psychomotor develop-
mental index scores in 7-mo-old infants (263).
Studies on a small sample of infants (n =
38) from the Netherlands focused exclusively
on developmental outcomes associated with
perinatal PCDD/F exposure, as determined by
measuring 7 PCDD and 10 PCDF congeners in
breast milk samples obtained within 3 wk after
birth (348,349). At age 5 to 7 d and 26 wk, the
Prechtl neurological optimality score did not
show an association with exposure level (348)
nor did the BSID scores show an association at
age 2 yr (349). The Hempel test of neuromotor
functioning revealed significantly enhanced
maturation in the high-exposure group, as
evidenced by significantly fewer suboptimal
scores. The authors hypothesized that dioxins
may have acted as thyroxine agonists because
they found that thyroid function in this cohort
was rather elevated in the high-exposure group
in the first 11 wk after birth (350,351).
Together, these data indicate that prenatal
or perinatal exposure to PCBs and possibly
PCDD/Fs adversely affects neurodevelop-
ment. However, we emphasize that the vari-
ous neurodevelopmental parameters were in
the normal range, even at the highest exposure
levels. It is highly unfortunate that differences
in study design, in the reporting of quantita-
tive exposure data and the outcomes associ-
ated with them, and in the number and types
of confounders considered in the statistical
analyses, as well as inconsistencies in some of
the results, seriously hamper comparison of
the results. Additionally, the differences in
the reported outcomes make an evaluation of
the effect size difficult. Ultimately, however,
the fact that there is any effect at all is of para-
mount concern.
Effect of OCs on Thyroid Hormone Status
In vitro and animal studies have shown
that PCBs and their hydroxylated metabolites
can induce various enzymes involved in the
metabolism of thyroid hormones and can dis-
place thyroid hormones from their binding
proteins (276). Both of these mechanisms are
likely to contribute to the decreased plasma
levels and reduced availability of T4 and T3
observed in experimental animals. Reduc-
tions in brain T4 concentrations have also
been reported, but brain T3 levels are fre-
quently unaffected, suggesting the existence of
effective compensatory mechanisms. In utero
exposure to single PCB congeners was associ-
ated with reduced plasma T4 levels in rat pups,
and reduced T4 levels were also observed in
wildlife species. Results of thyroid-stimulating
hormone (TSH) levels are inconsistent. Learn-
ing and behavioral deficits as well as reduc-
tions in auditory evoked potentials have been
observed in rodents and monkeys perinatally
exposed to PCBs. These manifestations resemble
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those induced by fetal hypothyroidism, but a
causal link between the neurodevelopmental
and the thyroid effects of PCB exposure cannot
be established using the available data.
High levels of environmental exposure to
OCs (as experienced by Inuit and other coastal
populations in which the traditional diet includes
fish and the meat and blubber of sea mammals)
have also been reported to affect neonatal thy-
roid hormone status. In a comparison of vari-
ous populations in the Québec province,
concentrations of total PCBs (49 congeners)
and total OH-PCBs (15 congeners) in cord
blood both showed significant negative corre-
lations with TSH concentrations but were not
associated with levels of T3 or free T4 (279).
Notably, in those cord plasma samples, the
major chlorinated phenolic compound was
pentachlorophenol, and it was negatively cor-
related with T3, free T4, and thyroxine-bind-
ing globulin.
In the Faroese birth cohort, more frequent
maternal fish consumption during pregnancy
was significantly associated with decreased
TSH concentration, but not T4 levels, in neona-
tal blood samples obtained 4 to 7 d after birth
(352). A slight tendency for TSH and T4 to
decrease with increasing PCB concentrations
in umbilical cord tissue was no longer evident
after adjustment for the frequency of maternal
fish consumption during pregnancy.
When stored cord-blood samples form 160
of the children from the North Carolina cohort
were assayed for free and total T4 and TSH,
their levels were not found to be associated
with the originally measured average PCB con-
centrations in mother’s milk and serum that
had been scaled to be comparable with the
level in milk at birth (353).
In the Dutch cohort, higher values for the
sum of all TEQs from dioxins or planar or
nonplanar PCBs in a 24-h representative breast
milk sample obtained during the second week
after delivery were significantly correlated
with decreased maternal plasma levels of total
T3 and T4 (354). The TEQ sum of dioxins (di-
oxin TEQ), dioxins and dioxin-like PCBs (total
PCB-dioxin TEQ), and PCBs (PCB TEQ) were
all positively correlated with plasma TSH lev-
els in the infants at ages 2 wk and 3 mo. Infants
exposed to dioxin levels greater than the median
exhibited significantly decreased mean plasma
total T4 and increased plasma TSH levels in the
second week after birth, whereas only TSH lev-
els were increased in umbilical cord plasma
and plasma obtained 3 mo after birth.
In marked contrast, in 38 Dutch neonates,
T4 concentrations were increased at birth (in
cord blood) and at ages 1 and 11 wk in the
group in which mothers’ breast milk contained
high levels of dioxin (29.2–82.7 TEQ/kg milk
fat) compared with the group with low expo-
sure (351). Thyroxine-binding globulin was not
significantly different at birth and at age 1 wk
but was significantly higher in the group with
high exposure at age 11 wk. Notably, the more
highly exposed children in this cohort had sig-
nificantly fewer suboptimal scores on the
Hempel test of neuromotor functioning, sug-
gesting enhanced maturation (349). The authors
hypothesized that this could result from the
thyroxine agonist activity of dioxins. Elevated
serum T3 and T4 concentrations, but normal
TSH levels, have been reported in Yusho patients
compared with unexposed controls; however,
they do not correlate with PCB levels, suggest-
ing that the effect is mediated by PCDFs or
other thermal breakdown products of PCB
(355).
Particulate Matter
PM consists of a complex mixture of organic
and inorganic liquids and solids in the form of
particles of different sizes and structures. The
precise mixture varies by region and season.
For example, PM in the northeastern United
States has a high sulfate content (approx 40%
by mass), whereas nitrates and organic com-
pounds comprise approx 30% of the mass of
PM in parts of the western United States (356).
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Within a given area, there can be substantial
differences between winter and summer par-
ticulate air pollution concentrations; some areas
show peak levels in the summer because of pho-
tochemical reactions, whereas other areas are
more polluted in the winter because of increased
emissions resulting from heating, and yet others
show little seasonal variation (356–359).
Particles with a 50% cut-off aerodynamic
diameter of 10 µm (PM10) can be inhaled into
the lungs and, therefore, are referred to as tho-
racic, respirable, or inhalable particles. Since
1987, mass concentration of PM10 has been used
in setting the US National Ambient Air Qual-
ity Standard for particulate air pollution (for
comparison, see Table 15, which also shows
values from Canada and the European Union).
PM10 consists of fine particles with an aerody-
namic diameter of 2.5 µm (PM2.5) and coarse
particles (PM2.5–10), and the contribution of
PM2.5 to PM10 was relatively constant in a given
area but varied between 35 and 80% by region
(356). In 1997, the EPA proposed standards for
PM2.5 (see also Table 15). PM2.5 can be further di-
vided into nucleation mode or ultrafine particles
(UFPs) with an aerodynamic diameter less
than 0.1 µm and accumulation mode particles
(approx 0.1–1 µm). Whereas measurements of
larger particles are commonly based on their
mass concentration, UFPs have very little mass
but comprise the vast majority of the total
number of particles. Therefore, they are mea-
sured as number concentration.
In Europe, there is a rather longstanding
tradition of assessing levels of black smoke,
which consists of black particles with an aero-
dynamic diameter less than 4.5 µm and mea-
sures elemental carbon (EC). Based on the once
valid assumption that black smoke originated
mostly from burning coal, the OECD defined a
standard of converting reflectance of these
black soot particles into mass concentration.
These standards are no longer appropriate
because coal burning has decreased consid-
erably in most industrialized countries over
recent decades. Today, an estimated 60 to 90%
of the atmospheric EC content is produced by
diesel-powered vehicles. It is estimated that
more than 80% of diesel exhaust particles have
an aerodynamic diameter of 1 µm or less (360).
Nonetheless, compared with purely gravimet-
ric methods, measuring reflectance has the
major advantage of providing some important
information on the composition of particles.
Particle Sources
Coarse particles are generated from soil and
other crustal materials mostly by the mechani-
cal processes of agriculture, mining, construc-
tion, and road traffic, but they also include
particles of biological origin, such as pollen
and fungal spores. The most important sources
Table 15
Ambient Air Quality Standards
Agency PM10 Averaging time PM10 PM2.5 Averaging time PM2.5
US EPA 50 mg/m3 Annual 15.0 mg/m3 Annual
US EPA 150 mg/m3 24 h 65 mg/m3 24 h
EU (Europe) 40 mg/m3 Annual
EU (Europe) 50 mg/m3, not to be 24 h
exceeded more than
35 times a calendar year
TSPa
Canada 70 mg/m3 Annual
120 mg/m3 24 h
aTotal suspended particles (TSP) are the only category of PM for which standards are set in Canada.
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of fine particles are incomplete combustion
processes, formation of secondary particles via
gas-to-particle reactions, and coagulation pro-
cesses in the atmosphere. To varying degrees,
ambient urban PM levels depend on both pri-
mary regional emissions and long-range trans-
port.
Indoor particle concentrations are deter-
mined by the concentration of particles outside
and the generation of particles indoors. The
contribution of outdoor PM2.5 to indoor levels
has been estimated to average between 30 and
80% for homes from different geographical
areas of the United States and Europe but can
vary from 0 to 100% between individual build-
ings within these areas (361–365). This large
variability results from the fact that the fraction
of indoor PM derived from outdoor sources de-
pends on various factors. These factors include
particle penetration efficiency, particle deposi-
tion rate, air exchange rate, and the extent of
particle generation during indoor activities of
the residents, which, in turn, are subject to cir-
cadian and seasonal variation (363,366–368).
The penetration efficiency of outdoor particles
has been found to be close to one independent
of particle size, indicating that building shells
essentially do not filter particles nor do they
provide protection from inhalation exposure to
ambient PM (363,366,367). However, the effec-
tive penetration efficiency or infiltration effi-
ciency (defined as the equilibrium fraction of
ambient PM that penetrates indoors and remains
suspended) depends on particle size because
larger particles have higher deposition rates,
whereas resuspension involves almost exclu-
sively particles greater than 1 µm (366–368).
The most important indoor source of par-
ticles is ETS (361,366,369–373). Considerable
generation of particles also occurs during cook-
ing and certain cleaning activities; vacuuming
and the overall movement of people resuspend
particles and contribute to indoor concentra-
tions (363,366,374,375). Notably, one of these
studies has provided evidence that terpene-
ozone reactions can result in pronounced eleva-
tions in fine particles and UFPs (375). As pre-
viously discussed, the products of terpene-O3
reactions have been shown to act as strong air-
way irritants (32,33). ETS results in elevated
particle counts in all size ranges, but appears
to more strongly affect the size fraction smaller
than 1.0 µm (376). Cooking is one of the major
indoor sources of UFP, with frying, toasting,
baking, and barbecuing generating particles
mostly in the ranges of 0.02 to 0.1 µm and 0.1 to
0.5 µm (357,370,375). Sautéing produces par-
ticles both in the ultrafine and coarse modes
(2.5–10 µm). Although dusting, vacuuming,
and walking constitute important sources of
PM2.5, they predominantly raise the concentra-
tions of coarse particles (357,375). Note that in-
door particle events are brief and intermittent
and not only have a pronounced effect on the
size distribution of particles but can also raise
particle number concentrations up to 100-fold
and can result in peak mass concentrations that
are several orders of magnitude higher than the
values obtained from time-integrated samples
(375).
Exposure
Tables 16 and 17 summarize the results of
recent studies that measured indoor, outdoor,
and personal exposure levels to PM10 and
PM2.5. These data highlight that there are con-
siderable regional differences in ambient con-
centrations of particulate air pollution not only
worldwide but also within the United States.
They further show that for both PM10 and PM2.5,
personal exposure frequently exceeds residen-
tial indoor and residential and/or ambient out-
door concentrations, and in many of these
studies, residential indoor levels are also elevated
compared with those measured outdoors. Con-
sequently, personal exposure can exceed
Ambient Air Quality Standards in a substan-
tial portion of the population, even if outdoor
concentrations meet the standards (366). The
excess personal PM exposure compared with
indoor and outdoor PM concentrations is re-
ferred to as the “personal cloud.”
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There is still uncertainty regarding the fac-
tors that contribute to this excess, but ETS,
cooking, cleaning, and other indoor activities
are all important (377,378). Other microenvi-
ronmental exposures—particularly traveling
in vehicles—also significantly contribute
(376,378,379). Personal exposure overall is pre-
dicted by ETS and, in its absence, by residen-
tial indoor concentrations, followed by work
environment concentrations and traffic density
in the nearest street from home (371,380,381).
Outdoor PM2.5 levels only predicted personal
exposure in models that excluded residential
and workplace indoor concentrations (371).
This is consistent with the results of most cross-
sectional studies, which indicate that the cor-
relation between personal and outdoor PM
levels is weak to moderate (365,369,382). Con-
siderably stronger correlations have been re-
ported from most longitudinal studies—
especially in the absence of ETS exposure
(380,383–386)—even in elderly subjects who
spend an even greater percentage of their time
indoors and at home (387). Correlations between
personal and indoor particulate levels are fre-
quently stronger, even in cross-sectional stud-
ies (369,382,388). However, note that the strength,
magnitude, and even direction of the associa-
tions vary considerably among individuals
(384,385).
Lung Deposition, Clearance,
and Changes in Airways
Inhalation is the major pathway of expo-
sure to airborne particles, and adverse health
effects can occur when particles are deposited
in the lung or enter the systemic circulation via
the lung. The fractional deposition of fine par-
ticles and UFPs is fairly high, generally rang-
ing from approx 0.4 to 0.7 for UFPs, depending
on the nature and size of the test aerosol and
the breathing pattern (389–392). Total lung as
well as peak deposition within certain regions
of the lung depend on particle size, becoming
greater with decreasing particle size for par-
ticles less than 0.5 µm and with increasing par-
ticle size for particles greater than 0.5 µm
(389–394). The site of peak deposition also
depends on particle size, with the site of
maximal deposition shifting proximally with
decreasing particle size for particles less than
0.1 µm and with increasing particle size for par-
ticles greater than 1 µm (393,394). This entails
that local deposition dose can greatly exceed
the average dose of the entire lung. Whereas
fine and coarse particles deposit by gravita-
tional sedimentation and inertial impaction,
diffusion is the predominant mechanism of
deposition of particles for the UFP range and
up to a diameter of approx 0.3 to 0.5 µm. Peak
deposition of UFP was observed in a volumet-
ric lung region corresponding to the transition
zone between the conducting airways and alveo-
lar regions (394). Similarly, autopsy studies of
lung tissue from subjects who had lived in
areas with high particulate air pollution have
indicated that tissue retention of fine particles
is mostly observed in this transition zone (395).
There is some evidence that UFPs are not nec-
essarily retained in the lung but can diffuse
directly into the systemic circulation (396).
In healthy subjects, the magnitude of the
total deposition fraction for fine particles and
UFPs mainly depends on tidal volume and res-
piratory time and does not differ significantly
between young and elderly subjects using the
same controlled breathing patterns (391, 397,398).
Consistent with these observations, deposition
of UFPs (<100 nm) increases markedly with
exercise as a result of both increased minute
ventilation and an increase in the depositional
fraction (389,390). The influence of lung func-
tion parameters (functional residual capacity,
FEV1, and specific airway conductance) on the
deposition fraction appears to be essentially
negligible in healthy subjects (391,398). How-
ever, this is not applicable to patients with
obstructive airway disease. Results from sev-
eral recent studies indicate that deposition of
fine particles as well as UFPs is greater in patients
with asthma or chronic obstructive pulmonary
disease (COPD) than in healthy subjects (389,
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399,400), whereas clearance does not differ sig-
nificantly (400).
Examination of autopsy lungs indicates
that particles are retained in lung parenchyma
from residents of areas with low-to-moderate
air pollution (401) and that particle burden is
significantly higher in lungs from residents of
more highly polluted areas (402). A vast major-
ity of these particles have aerodynamic diam-
eters smaller than 2.5 µm, but UFPs constitute
only a small fraction of the total (401). Such
studies further show that retention of fine par-
ticles occurs primarily in terminal and respi-
ratory bronchioles and is associated with
inflammatory changes and small airway remod-
eling that may contribute to chronic airflow ob-
struction (395,403,404).
Epidemiological Studies of Health Effects
In an ever-growing number of time series
studies from around the world, short-term
increases in PM10 (or black smoke) are sta-
tistically associated with increased cardiopul-
monary morbidity and mortality (405–407).
Conversely, there are indications that reduc-
tion of particulate air pollution is associated
with a significant decrease in daily mortality
(408). Fewer studies have addressed the effects
of fine particles, but studies that have analyzed
both PM10 and PM2.5 have provided evidence
of much stronger associations of morbidity and
mortality with the fine fraction (409–411). High
correlations between PM and other air pollut-
ants have been reported in some locations, and
other criteria pollutants have also been linked
to increased morbidity and mortality (407).
However, at least part of the effect of PM ap-
pears to be independent of other air pollutants,
and it remains a matter of debate whether gas-
eous pollutants are confounders, effect modi-
fiers, or actual surrogates for PM exposure
(359,412,413).
Effect estimates for the increase in overall
mortality associated with a 10 µg/m3 increase
in PM10 range from approx 0.2 to approx 0.7%
(359,414,415,416). Corresponding estimates for
cardiorespiratory mortality are usually consid-
erably higher, and there is a markedly greater
increase in respiratory compared with cardio-
vascular mortality (415,417). However, because
cardiovascular disease affects far more people,
the absolute number of cardiovascular deaths
associated with particulate air pollution is
substantially greater than that of respiratory
deaths.
Cross-sectional time series suffer from the
inability to control for confounding factors
such as smoking, alcohol consumption, diet
and nutrition, body mass index, occupational
exposure, and socioeconomic factors. How-
ever, the results from several large prospective
cohort studies, in which such corrections are
possible, have not only confirmed that higher
ambient particulate pollution levels are associ-
ated with significant increases in deaths from
lung cancer and cardiopulmonary disease but
have yielded much larger effect estimates
(409,418). The results of the Harvard Six Cities
Study (409) were independently validated
(419). In a recent extended follow-up of one
of the American Cancer Society cohorts, an
increase in annual mean PM2.5 concentration
was found to correlate with increases in all-
cause, cardiopulmonary, and lung cancer
mortality of at least 4, 6, and 8% of subjects,
respectively; the estimate depended on the
time period during which PM2.5 levels were
measured (410). All other causes of mortality
were not associated with particulate air pollu-
tion. In partial contrast, in a cohort of non-
smoking Seventh-Day Adventists, ambient
concentrations of PM10 were significantly asso-
ciated with all-cause mortality in both genders
and with lung cancer deaths in males only but
were not associated with cardiopulmonary
mortality (420). However, there was a signifi-
cant association with deaths for which the
death certificate made any mention of nonma-
lignant respiratory disease as an underlying or
contributing cause of death.
There are indications that the elderly and
people with underlying heart disease, respira-
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tory disease, or diabetes are more susceptible
to the adverse effects of particulate and other air
pollution (421–423). Nonetheless, the increase in
daily mortality associated with particulate air
pollution does not appear to be simply “ pre-
mature harvesting”—that is, the advance-
ment of death by a few days in individuals
with severe illness. Instead, some recent analy-
ses have suggested that particulate air pollu-
tion shortens life expectancy by at least several
months (424,425). Additionally, consistent with
the results of prospective studies, the effect size
estimates become considerably larger when
longer lag periods are considered (417,425).
We emphasize that although the effects of
acute PM exposure on mortality are very
small, a vast majority of the world population
is exposed to this type of pollution, making the
number of premature deaths associated with
this exposure substantial. A recent estimate stated
that 800,000 deaths worldwide are attributable to
particulate pollution alone, of which approx
65% occur in Asia (426). Note that adverse effects
associated with particulate air pollution are evi-
dent at levels below the standards set by vari-
ous governmental and supragovernmental
agencies. Furthermore, the relationship between
PM concentrations and adverse health effects is
essentially linear, and there does not appear to
be a threshold below which exposure can be
considered safe (405,406).
The biological plausibility of a causal asso-
ciation between particulate air pollution and
adverse cardiovascular and respiratory health
effects is supported by the fact that adverse
effects of particulate and other air pollution on
mortality and morbidity have rather consis-
tently been reported from numerous areas
worldwide with widely differing mixtures of
air pollutants, absolute levels of PM, particle
sources, and, therefore, particle composition.
However, there are considerable differences in
the size of the effect estimates. This is most
likely attributable to differences in absolute
exposure levels, particle sources, and their size
distribution and composition, but may also in-
clude differences in the subjects and in the defi-
nitions of outcome measures. Further evidence
of plausibility comes from the finding that PM-
associated adverse health effects cover a con-
tinuous spectrum of severity (406). In addition
to increased mortality, this spectrum includes
increased hospitalizations for cardiovascular
and respiratory diseases (412,427,428), emer-
gency department and other health care visits
for asthma and other respiratory symptoms
(407,429–431), prevalence of atherosclerosis
(432), decreased lung function and lung func-
tion growth (433–439), and increased respiratory
infections and respiratory symptoms (440,441).
Associations of PM10 With Lung Function,
Symptoms, and Medication Use
In addition to cross-sectional and prospec-
tive cohort studies, panel studies have become
an important tool for assessing the effects of
particulate pollution on respiratory and other
health outcomes. Such studies use repeated
measurements of the outcome of interest in a
fairly small group of subjects and correlate
them with daily changes in ambient concentra-
tions of PM and other air pollutants, which are
generally obtained from central monitoring
sites.
A significant association between particu-
late pollution and declines in PEFRs as well as
increased prevalence of cough and lower res-
piratory symptoms has been reported in some
panels of unselected children (442,443) but not
in others (444). In other studies, only children
with asthma or asthmatic symptoms appeared
to be susceptible to the effects of particulate air
pollution (445,446). Similarly, in panels of
unselected adults, associations of PM and other
air pollutants with increases in the prevalence
of decrements in PEFR greater than 20 or in res-
piratory symptoms were only observed in
those with chronic respiratory symptoms or
increased airway lability but not in those with-
out (447,448).
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Such findings suggest that patients with
obstructive airway disease are more suscep-
tible to the adverse effects of particulate air
pollution. Therefore, most panel studies have
focused on children and adults with asthma or,
more rarely, COPD. Significant negative asso-
ciations between daily fluctuations in PM10 and
PEF deviation or prevalence of PEF decrements
greater than 10 and 20% have been reported in
asthmatic children (406,445,449–454). An asso-
ciation of borderline significance was also
noted in one panel of patients with COPD
(455). These are not entirely consistent findings
(456–459). Notably, no effect of PM10 on PEFR
were observed in the Pollution Effects on Asth-
matic Children in Europe (PEACE) study, one
of the largest panel studies on air pollution and
respiratory health in children with chronic res-
piratory symptoms, involving more than 2000
children in 14 European centers (460). Even
stratification into more sensitive subgroups
did not yield any significant findings (461,462).
The association between exposure to PM10
and other lung function measures, such as FEV1
or FVC, has been investigated more rarely. Sig-
nificant negative associations between residen-
tial outdoor and, to a lesser extent, central site
PM10 values and FEV1 were observed in chil-
dren with asthma from southern California
(463). In a panel of 86 children with asthma
from Detroit, PM10 and 8-h peak O3 levels with
a 2-d lag showed a significant negative correla-
tion with diurnal variability in FEV1 and low-
est daily FEV1 value (450). However, others
were unable to detect an effect of PM10 on FEV1
or FVC (464).
In numerous panel studies of children and
adults with asthma, a significant association
has been detected between elevations in PM10
concentrations and increased incidence and
prevalence of cough, phlegm, specific respira-
tory symptoms, or symptom scores (406,448,
449,456,465–467). Similar associations have
been reported in patients with COPD (455,458).
Again, there have been studies that have not
confirmed these findings, including the large
PEACE study (457,459,460).
Some panel studies with asthmatic children
and adults have indicated that the prevalence
of asthma medication use rises during, or shortly
after, periods of elevated PM pollution (453,468–
472). Associations have been reported between
both bronchodilator and maintenance medica-
tion use and various PM size fractions, includ-
ing PM10 and PM2.5 as well as UFPs. However,
others failed to observe a significant effect of
PM on the prevalence of asthma medication
intake or the daily dose (457,466,473).
Several studies have analyzed potential
interactions between the effects of anti-inflam-
matory medication use and exposure to ambient
PM on asthma symptoms and lung function
(449,450,457,461,463,465,470,474–478). In some
investigations, associations between PM and
increased symptoms and/or decreased lung
function were only noted, or were stronger, in
those subjects who were taking anti-inflam-
matory medication (449,450). This was even
reported from panels whose prevalence of
asthma medication use increased in association
with elevated particulate pollution (470,474).
Note that this increased overall medication use
did not necessarily affect the associations of PM
with lung function in the same way it influenced
the association with symptoms (470,474). Oth-
ers were unable to detect a significant interac-
tion between the effects of anti-inflammatory
medication use at baseline and PM10 exposure
on asthma symptoms (466) or lung function
(FEV1) (463). Finally, there have also been stud-
ies in which particulate air pollution signifi-
cantly affected lung function, exhaled NO
(476,477), or symptoms (457,475) to a much
greater extent, or exclusively in children who
did not take inhaled corticosteroids.
Some of these discrepancies may have re-
sulted from the fact that some studies assessed
medication use only at baseline, whereas oth-
ers assessed medication use during the entire
follow-up period. Additionally, the effects of
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particulate pollution on lung function and
symptoms were observed at different lag and
averaging times in the various studies. The
averaging time for particulate concentrations,
symptom severity of the subjects, and medica-
tion use were all found to have a major impact
on the association between PM pollution and
increased symptom scores in a study of 25 chil-
dren and adolescents with asthma in southern
California (465). The largest effect of 24-h mean
PM10 concentrations was noted in less symp-
tomatic children who did not take anti-inflamma-
tory medications, whereas more symptomatic
asthmatics showed the greatest increase in
symptoms in association with short-term PM10
excursion (1-h means). No association between
PM10 at any averaging or lag time could be
detected in subjects who took anti-inflamma-
tory medications, whereas nonmedicated sub-
jects exhibited large and significant increases
in symptom scores in association with same-
day 8-h maximum and 24-h mean PM10 levels
as well as with their 5-d moving averages.
Overall, the available data suggest that anti-in-
flammatory medication and possibly bron-
chodilator use provide some protection from
the effects of particulate pollution on lung func-
tion and symptoms in patients with asthma.
Protection may be incomplete if the type or
dose of medication is inadequate. In some patient
groups, however, medication use appears to be
a marker of asthma severity, which confounds
the protective effects of anti-inflammatory
therapy.
Interactions have been observed not only
with medication use but also with respiratory
infections. In a panel of 86 children with asthma
living in Detroit, both PM2.5 and PM10 were sig-
nificantly associated with decreased lung func-
tion in children with upper respiratory infections
with a 3- to 5-d lag, whereas PM2.5 did not show
significant effects in the absence of upper res-
piratory infections (450). Others did not detect
a significant interaction between the effects of
respiratory infections and concentrations of
particulate air pollution on percent predicted
FEV1 (463). When symptom severity was the
outcome of interest, however, the same inves-
tigators found significantly stronger associa-
tions with various averaging times of PM10, O3,
and NO2 during respiratory infections, with
some of the ORs increasing up to fivefold (475).
Associations of PM2.5 With Lung Function,
Symptoms, and Medication Use
Routine monitoring of PM2.5 began in the
United States only after standards for this size
fraction were proposed in 1997, and it is still
not performed in most European countries.
Therefore, fewer studies have investigated the
effects of fine PM on respiratory health. Re-analy-
sis of data from three large panel studies revealed
a significant association between PM2.5 and
increased prevalence of lower respiratory
symptoms as well as decreased evening PEF,
with the strongest association noted with sul-
fate fine particles (443). Conversely, in several
panels of children and adults with asthma or
asthmatic symptoms, exposure to varying con-
centrations of PM2.5 essentially did not corre-
late with PEF (464,473,479). Ambient fine
particulate concentrations were significantly
associated with decreased FEV1 in asthmatic
children both in an area where residential
wood burning heavily influenced PM con-
centrations (446) and in an area affected by
long-range transport of mostly traffic-related
combustion products (463). Additionally, fine
particles derived predominantly from wood
burning showed a significant association with
decreases in FVC (446). Conversely, FEV1 and
lowest daily FEV1 values did not correlate
with PM2.5 in asthmatic children from Detroit,
although in combination with O3, PM2.5 had
highly significant effects on both variability
and lowest daily values of FEV1 (450). The risk
of lower respiratory symptoms and cough was
also found to increase with elevated levels of
ambient PM2.5 (466,479), as was medication use
(468,469).
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Associations With Personal PM
One of the few studies to monitor personal
PM10 and PM2.5 exposures in children with
asthma found that their associations with FEV1
were significantly stronger than those of any
of the stationary site measurements, which
included indoor home, outdoor home, and
central site monitoring (463). The strongest asso-
ciation was demonstrated with an interquartile
increase in mean 12-h daytime 5-d moving
average of personal PM exposure, which was
associated with a 22% decrease in FEV1. In
another panel study of subjects with asthma
from Toronto, Canada, FVC, FEV1, and forced
expiratory flow25–75 (FEF25–75) were not signifi-
cantly associated with personal particulate
exposure, but there was considerable con-
founding by increased use of asthma medica-
tion (480).
Re-analysis of data from three large panel
studies indicated that fine particles—particu-
larly fine sulfate particles—were more strongly
associated with increased lower respiratory
symptoms and decreased evening PEF than the
coarse fraction (443). However, other studies
have provided little indication that the effects
of fine particulate matter (PM2.5) are stronger
than those of PM10. Rather, in the few available
direct comparisons, PM10 actually was found to
have slightly stronger independent effects on
FEV1 (450,463) and symptoms in children with
asthma (466) and on PEFR in unselected chil-
dren (442). As we later discuss, in the context
of possible mechanisms, there are some indica-
tions that the ultrafine size fraction of PM may
affect respiratory outcomes more strongly than
fine or inhalable particles, but the available
data are inconclusive.
Confounders and Effect Sizes
Note that PM can correlate moderately to
highly with other air pollutants—in particular,
O3, NO2, and SO2. When one or more of these
pollutants were analyzed with PM, they fre-
quently had similar or stronger effects on res-
piratory outcomes (445,456,457,465–467,472,
475). Two-pollutant models indicate that the
effects of PM often are at least partly indepen-
dent of those of other pollutants (442,450,465),
but there are also instances where inclusion of
gaseous pollutants in the model abrogates the
significance of the PM effects (475,478). Con-
versely, abrogation of the effects of other pollut-
ants by PM has also been described (442,463),
suggesting that the effects of air pollution most
likely result from complex mixtures rather than
a single agent.
It has been estimated that a 10-µg/m3 increase
in the concentration of ambient PM10 is associ-
ated with an increase of approx 3% in the
prevalence of lower respiratory symptoms
(406,407). Effect size estimates for decrements
in lung function are considerably lower, with
an estimated decrease of 0.15% in FEV1 and a
decrease of 0.08% in PEF in association with a
10-µg/m3 increase in PM10. The prevalence of
decrements in PEF greater than 10 and 20%
may constitute a more clinically relevant out-
come measure (454). Re-analysis of five panel
studies indicated that a 10-µg/m3 increment in
PM10 on the same or the previous day was associ-
ated with increases of 2.7 and 2.4%, respectively,
in the prevalence of decrement in PEF greater
than 10%. The increases in the prevalence of
PEF decrements greater than 20% were some-
what larger.
Lag Times
Panel studies generally investigate the effects
of PM exposure on the same day (lag 0) as the
assessment of the outcome in question, on 1 to
4 d prior, or averaged over a few days. Although
associations have been detected between same-
day PM10 concentrations and the prevalence of
decrements in PEF greater than 20% (454,470),
other results have indicated that the highest
effect estimate was obtained with 5-d mean
levels (454). The largest effect of PM10 levels on
PEF deviation was also noted very consistently
with 4- or 5-d averages in ambient PM10 con-
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centrations (445,451,470,473). This contrasts
with the results of a study in healthy children,
who exhibited the greatest PM10-asscoiated
decrease in PEF immediately following the 24-h
monitoring period, whereas no association was
observed with 5-d moving average concentra-
tions (442). This may suggest that the effects of
particulate pollution on lung function in healthy
and asthmatic children are mediated by differ-
ent mechanisms.
Some of the effects of PM10 and PM2.5 on
FEV1 and FVC appear to be more immediate
because significant correlations with same-day
ambient concentrations were reported in at
least one study (446), and associations with
same-day indoor and personal 12-h daytime
exposures were noted in another (463). Consid-
erations of 2- and 4-d lags did not significantly
alter the observed associations in one case
(446); in the other study, the strongest effects
were observed for 5-d moving averages of
PM2.5 and PM10 concentrations (463). Diurnal
variability of FEV1 and lowest daily FEV val-
ues were found to be affected most strongly
2 d after exposure to PM10, whereas the aver-
age daily exposure of 3 to 5 d before the FEV1
measurement was not significantly associated
with these outcomes (450). Note that unlike the
preceding study, exposure was not averaged
over all five preceding days. However, both
PM2.5 and PM10 concentrations with a 3- to 5-d
lag significantly correlated with both FEV1
measures in children with upper respiratory
infections.
Although symptoms were exclusively asso-
ciated with same-day exposure to PM10 in some
studies (449,467), other investigators found ef-
fects only after lags of at least 2 d (466), and 2- to
5-d mean PM10 concentrations exhibited the
strongest associations with symptoms in several
other panels (455,456,470). Medication use is
quite consistently found to be associated most
strongly with 5-d mean PM10 concentrations
(469–471), and strong effects have also been
reported with 14-d cumulative exposure (469).
Notably, it has been reported that symptom
scores in children with asthma were more
strongly associated with 1- and 8-h maximum
PM10 than with 24-h PM10 levels (465,475). Oth-
ers have also described an association of symp-
toms with 1-h peak PM10 concentrations (466).
This suggests that brief excursions may have a
more pronounced effect on asthma symptoms,
and possibly lung function, than the 24-h inte-
grated concentrations on which most epide-
miological studies are based.
Overall, exposure to particulate air pollu-
tion appears to have both acute and somewhat
more chronic and cumulative effects. This
suggests that several different mechanisms
are involved. Whereas the acute effects could
result from irritant effects of particulate air
pollution, effects noted after considerable lag
periods may involve inflammatory processes
that take several days to fully develop. It is also
possible that exposure to particulate and other
air pollutants primes the immune system for
increased responses to subsequent allergen
exposure.
Mechanisms
The underlying mechanisms through which
particulate pollution may contribute to increased
cardiopulmonary morbidity and mortality are
incompletely understood. It has been hypoth-
esized that UFPs are primarily responsible for
the observed health effects because they make
up a vast majority of the overall number of par-
ticles and are more likely than larger particles
to reach the alveoli (481). According to this
hypothesis, UFPs deposited in the alveoli
would trigger an inflammatory response with
subsequent release of inflammatory mediators
that could not only exacerbate lung disease
but could induce systemic inflammation and
prothrombotic changes in the blood (481). This
hypothesis is partly based on the finding that
UFPs can cause pulmonary inflammation in
rats, whereas larger particles with the same
composition cannot (482,483). Particle compo-
CRIAI_31_Final Appl 7/17/06, 1:48 PM60
Airborne Environmental Injuries and Human Health 61
Clinical Reviews in Allergy & Immunology Volume 31, 2006
sition, rather than mass, has been shown to be
associated with pulmonary inflammation (484),
and small particles have larger surface areas
and contain higher concentrations of soluble
transition metals, organic compounds, sulfates,
and nitrates. All of these constituents have
been implicated in the induction of oxidative
stress and inflammatory changes in vitro and
in experimental animals (485–490).
Consistent with the hypothesis that sub-
micrometer particles are mainly responsible
for the adverse health effects of particulate air
pollution, PEF was more strongly associated
with the 5-d mean number of UFP particles
than with the mass concentration of fine par-
ticles in a panel of adult asthmatics from Erfurt,
Germany (491). The effects of number concen-
trations of various size fractions of UFPs and
mass concentrations of PM were also compared
in adult patients with asthma from Helsinki
(464,473). In these studies, number concentra-
tions of UFPs, but not particle mass in any size
range, were negatively associated with PEF
deviations but not with respiratory symptoms
or medication use.
Conversely, in a study involving children
with asthmatic symptoms from a smaller town
in eastern Finland, PM10 and black smoke were
significantly associated with decreased morn-
ing PEF, whereas particle number concentra-
tions were not (451). Only nonsignificant
inverse associations were observed with some
of the six measured size ranges (0.01–0.032
to 3.2–10). Similar findings were reported in
patients with COPD (455).
Others found PM2.5 and UFPs to be simi-
larly associated with symptoms in adult patients
with asthma (469). In a panel of elderly subjects
with coronary heart disease from three Euro-
pean countries, elevated levels of ambient fine
particles increased the risk of shortness of
breath, whereas avoidance of activities was
significantly associated with UFPs and was non-
significantly associated with PM2.5 (492). Finally,
exposure to ambient PM2.5 and UFPs indepen-
dently increased the risk of ST-segment depres-
sion during exercise, which is an indicator of
myocardial ischemia (493).
These results do not confirm the hypoth-
esis that UFPs are responsible for most of the
adverse health outcomes associated with par-
ticulate pollution. Instead, they indicate that
the contribution of fine, and possibly coarse,
particles should not be neglected. However,
evidence is accumulating to support the hypoth-
esis that pulmonary and systemic inflammation
and prothrombotic changes play important
roles in the health effects of particulate air pol-
lution.
Evidence of Inflammation
Exhaled NO is generally considered a marker
of inflammation in the lung. In unselected co-
horts of Dutch schoolchildren, elevations in
PM10, black smoke, NO, and NO2 were signifi-
cantly associated with exhaled NO (444,452).
Additionally, there was an increase in NO
metabolites, IL-8, and uric acid in nasal lav-
age in response to some of these pollutants
(452). Generally, greater effects were noted in
urban compared to suburban children. A panel
study of 19 children with asthma in Seattle,
Washington, also found that elevations in per-
sonal, residential indoor, residential outdoor,
and central site monitoring PM2.5 levels were
significantly associated with increases in exhaled
NO (476). The effect was restricted to children
not taking inhaled corticosteroids.
Young healthy volunteers from the Chapel
Hill, North Carolina, area were submitted to
controlled exposure to concentrated ambient air
particles (CAPS) at concentrations between 23.1
and 311.1 µg/m3 for 2 h with intermittent exer-
cise; this exposure induced mild pulmonary
inflammation in the subjects with the highest
exposure compared with those exposed to fil-
tered air (494). This was evident in a signifi-
cant increase in the percentage and absolute
numbers of neutrophils in bronchial and
bronchoalveolar lavage fluid (BALF) obtained
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18 h later, although total cell count increased
only in BALF. However, BALF concentrations
of inflammatory cytokines and other media-
tors, such as IL-6, IL-8, prostaglandin E2, α1-
antitrypsin, and fibronectin, did not change
(494), nor did expression of activation markers
on bronchoalveolar lavage or peripheral blood
lymphocytes or alveolar macrophages (495).
Blood fibrinogen increased after exposure to
CAPS, but the change was not statistically sig-
nificant.
Somewhat different results were obtained
in healthy and asthmatic adults from the Los
Angeles area who were exposed to CAPS (496).
Analysis of induced sputum obtained approx
22 h after exposure did not provide evidence
of pulmonary inflammation, because the white
blood cell count, differential cell counts, IL-6,
and IL-8 did not change significantly after
CAPS exposure compared with filtered air
exposure. Lung function and respiratory
symptoms were also not affected. However,
there were some indications of systemic inflam-
mation because plasma-soluble ICAM-1 con-
centrations were increased following CAPS
exposure in both groups. Additionally, plasma
IL-6 increased during exposure to filtered air
and to CAPS in both healthy subjects and
asthmatics, but the increase was greater after
exposure to CAPS than after air exposure in
asthmatics, whereas the healthy subjects
showed smaller increases after exposure to
CAPS than after air exposure. There were no
significant CAPS-induced changes in serum
amyloid, fibrinogen, von Willebrandt factor,
and factor VII. A notable difference between
the studies was that the targeted ventilation
rate was considerably lower in Los Angeles
(15–20 L/min/m2) than in Chapel Hill (25 L/
min/m2). The resulting lower exposure from
decreased deposition fraction together with the
use of induced sputum rather than BALF in the
Los Angeles group might partly explain why
the results of the two studies differed. Differ-
ences in particle composition may also have
contributed to the discrepant results.
There have also been several studies in
which healthy volunteers were exposed to
whole diesel exhaust (497–499) or diesel exhaust
particles (500). No significant changes in lung
function (as assessed by FEV1, FVC, FEF50, and
FEF25—75) were noted in healthy volunteers
exposed to whole diesel exhaust (497,498).
However, when the more sensitive method of
whole-body plethysmography was used, sig-
nificant increases in airway resistance and spe-
cific airway resistance became evident after
diesel exhaust exposure compared with expo-
sure to air, although it could not be established
whether this resulted from the particulate frac-
tion or other constituents of diesel exhaust
(497).
Indicators of pulmonary inflammation in-
cluded increased numbers of neutrophils
and B-cells and raised levels of histamine and
fibronectin, but not IL-8 and soluble ICAM-1,
in BALF obtained 6 h after exposure to diesel
exhaust (498). Bronchial biopsy samples also
exhibited elevated numbers of neutrophils,
mast cells, and total T-cells in submucosa and
epithelium along with enhanced expression of
adhesion molecules and their ligands in bron-
chial tissue (498). A marked rise in neutrophils
and platelets in peripheral blood suggested a
systemic inflammatory response. BALF obtained
24 h after exposure to diesel exhaust still con-
tained increased numbers of neutrophils and
also showed a significant rise in the number
of alveolar macrophages and particularly of
lysozyme-positive macrophages (501). Unlike
the result observed in 6-h samples, neither
fibronectin nor tryptase or ECP were elevated.
Similar findings have been reported after
healthy volunteers have been exposed to die-
sel exhaust particles (500). Specifically, airway
inflammation was evident in a small, but con-
sistent and significant, increase in neutrophils
and myeloperoxidase in induced sputum but
was not evident in IL-8 and TNF-α. In this
study, plasma IL-6, TNF-α, and P-selectin were
measured as markers of systemic inflamma-
tion and were found not to change signifi-
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cantly after exposure to diesel exhaust par-
ticles compared with exposure to air.
Nonetheless, indications of systemic inflam-
mation in response to PM exposure have also
been reported from cross-sectional and panel
studies. Increased white blood cell and platelet
counts were significantly associated with PM10
concentrations in a subsample of NHANES III
participants (502), although there was no asso-
ciation with PM2.5 levels in a panel of elderly
subjects (503) or in young healthy subjects
(504). An increase in the percentage of neutro-
phils was reported in highway patrol troopers
(505). Additionally, elevated levels of C-reac-
tive protein were found in association with
PM2.5 (503,505), PM10 (506), and total suspended
particles (507). Several authors also reported
that fibrinogen concentrations rose after expo-
sure to elevated concentrations of PM10 (502,508),
although this was not noted in young healthy
adults (504). Others detected a significant posi-
tive association between fibrinogen and O3 but
not PM10 (509). Fibrinogen is not only an acute
phase protein but is also a marker of hemostasis
because it plays a central role in coagulation.
Other hemostatic markers have also been re-
ported to be associated with PM2.5 exposure in
cars of highway patrol troopers (505) and with
PM10 and other ambient air pollutants (509). In-
creases in plasma viscosity were found during
an air pollution episode in Germany (510),
but no association was detected between
blood viscosity and PM2.5 concentrations in a
panel of elderly subjects from Utah (503).
Decreased Autonomic Control
Numerous panel and some cross-sectional
population-based studies (511,512) have inves-
tigated the association of PM10 and PM2.5 with
time- and frequency-domain parameters of
heart rate variability (HRV). In panel studies,
small, but significant, decreases in time domains,
such as the standard deviation of all normal-to-
normal intervals (SDNN) and the square root
of the mean of the sum of the squares of differ-
ences between adjacent NN intervals (r-MSSD)
were observed in association with daily fluc-
tuations in centrally monitored PM2.5 and PM10
concentrations (503,513,514) as well as in asso-
ciation with personal exposure to UFPs (515).
Frequency domains of HRV, such as high- and
low-frequency power, also showed small but sig-
nificant inverse associations with daily changes
in outdoor and indoor PM2.5 concentrations
(516,517) or the time-weighted total exposure
derived from them (518). They also decreased
significantly in association with fluctuation in
personal exposure to submicrometer particles
(515). The inability to detect significant effects
of PM2.5 and PM10 on HRV in some other panel
studies (519,520) likely results from the small
sample sizes, low absolute pollution levels in
both of the locations, low variability of PM2.5
measurements for most subjects, and, possibly,
differences in the composition of particles from
these cities compared with other metropolitan
areas.
Most of these panel studies were conducted
in elderly subjects, and there are indications
that the elderly are more susceptible to the
effects of particulate pollution on HRV than
younger adults (515). Susceptibility appears to
be further enhanced in subjects with underly-
ing cardiovascular disease (CVD) and hyperten-
sion (516,517), although others did not observe
a significant effect modification by CVD (518).
However, some effects on HRV have also been
reported in young subjects in association with
personal PM2.5 and UFP exposure (515,521),
with the effects of UFPs being smaller in young
subjects than in older subjects studied simulta-
neously (515). Additionally, brief occupational
and environmental exposures to PM2.5 were
significantly associated with decreased SDNN
in relatively young cohorts of boilermakers
(mean age: approx 40 yr) (522,523).
In striking contrast to the fairly consistent
finding of decreased HRV, in nine North Caro-
lina State Highway Patrol troopers, PM2.5 expo-
sure inside their vehicles was associated with
increased HRV and other changes suggestive
of increased vagal tone (505). Principal factor
CRIAI_31_Final Appl 7/17/06, 1:48 PM63
64 Borchers et al.
Clinical Reviews in Allergy & Immunology Volume 31, 2006
analysis of components of PM2.5 and associated
pollutants indicated that these changes were
associated most strongly with PM resulting
from brake wear and engine emissions (524).
This type of PM may exert different effects than
ambient particles from other sources. The results
of controlled exposure studies are also not
entirely consistent with these findings (496,
525). Note that particle concentrators used to
generate CAPS concentrate fine particles but
not UFPs. This could account for some of the
differences between the results of controlled
exposure studies with CAPS compared with
those of panel studies because UFPs were
shown to exert significant effects on HRV (515).
Overall, however, there is rather consistent
evidence that exposure to PM results in changes
in cardiac autonomic control, and the decreases
in SDNN in r-MSSD suggest reduced parasym-
pathetic tone. Exposure to particulate air pol-
lution is also associated with a decrease in
heart rate (511,513,526–528), which is consis-
tent with an increase in sympathetic tone; how-
ever, an association has not been evident in all
studies (503,514).
Types of Particles and Particle
Constituents Responsible
for the Observed Effects
Specific rotation factor analysis of the elemen-
tal composition of fine and course PM measured
in six US cities indicated that PM2.5 from mobile
sources (i.e., motor vehicle exhaust) showed the
strongest association with overall daily mortal-
ity, followed by particles from coal combus-
tion sources (529). Fine particles from crustal
sources were not associated with mortality.
Interestingly, a 10-µg/m3 increase in particles
from mobile sources was associated with a 2%
increase in deaths from ischemic heart disease,
but this was not statistically significant. An
adverse effect of traffic-related particles on res-
piratory deaths was not evident. Conversely,
deaths from COPD and pneumonia increased
with increased exposure to particles from coal
combustion sources, whereas this factor did
not affect deaths from ischemic heart disease.
Similarly, analysis of data from 14 US cities
regarding PM10 emissions by source category
indicated that hospital admissions for CVD
were most strongly correlated with increasing
percentage of PM10 from highway vehicles and
highway diesels (428). A correlation between
percentage of PM10 from highway vehicles/
diesels and hospitalization for COPD was not
observed for the entire data set but became sig-
nificant after exclusion of two cities (Boulder,
Colorado, and Provo-Orem, Utah).
These findings are consistent with reports
of increased mortality and morbidity in asso-
ciation with indicators of traffic (530) and traf-
fic-related air pollution, such as black smoke
and NO2 (531). Additionally, in several stud-
ies, (532,533), including some analyses of the
effects of air pollution on respiratory health
(448,453,457), some investigators found black
smoke to be more strongly associated with
adverse health effects compared with PM10 or
PM2.5 . EC and organic carbon are also likely to
be derived largely from traffic emissions. In
Hispanic children living in an area of Los Ange-
les with high traffic density, an asthma symp-
tom score was more strongly associated with
EC and OC than with PM10 (449). In two-pol-
lutant models that included EC and OC along
with PM10, the OR for PM10 was reduced to
1.0, whereas the ORs of EC and OC remained
unchanged.
The composition of PM does not vary only
by emission source; even ambient particles
used for CAPS studies show considerable day-
to-day variation in their OC, EC, and elemen-
tal composition (484,534). Huang et al. (534)
applied principal component analysis to data
from their study, which showed that controlled
exposure to CAPS from the Chapel Hill area
induced an increase in neutrophils in the bron-
chial and alveolar fraction and increased blood
fibrinogen levels in young healthy adults (494).
The results of this analysis indicated that among
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the water-soluble fraction of CAPS, a sulfate/
Fe/Se factor was associated with an increase
in the percentage of neutrophils in BALF and a
Cu/Zn/V factor was associated with increased
blood fibrinogen. This suggests that soluble
constituents of PM differentially affect target
organs and systems, which is consistent with
the findings of in vitro and animal studies sug-
gesting that particle-associated metals differ in
their ability to affect different cell types within
the lung and in the mechanisms by which they
operate (e.g., induction of oxidative stress or of
inflammatory cytokine production by lung epi-
thelial cells and alveolar macrophages) (486,
488,535).
These analyses were restricted to outdoor
particles. It has been suggested that ambient
stationary site measurements, as used in time
series and most panel studies, do not accurately
reflect personal exposures because people spend
approx 90% of their time indoors and the con-
tribution of outdoor particles to indoor concen-
trations varies widely between homes. Ambient
sampling has been shown to overestimate the
exposures resulting from traffic-related and
long-range transport sources and to underesti-
mate some significant indoor sources (of resi-
dential and indoor work environments) (536).
Additionally, the chemical composition of indoor
and outdoor particles can differ markedly (537,
538). Notably, some indoor and outdoor par-
ticles exhibited similar trace element composi-
tion, but scanning electron microscopy revealed
that spherical particles, usually indicative of
combustion or other high temperature indus-
trial processes, were present almost exclusively
in outdoor and ambient samples (537). Further-
more, indoor particles can have greater toxic-
ity than outdoor particles (539). Then, the issue
arises regarding whether indoor or outdoor
exposures are more relevant to the observed
health outcomes.
In a study that assessed personal exposure
to PM10 and PM2.5 in children with asthma
along with residential indoor and outdoor as
well as central-site PM concentrations, FEV1
was associated with the 5-d average of all mea-
surements but was most strongly associated
with personal exposure (463). Residential indoor
levels of PM2.5 and PM10 showed stronger asso-
ciations with FEV1 than residential outdoor or
central-site concentrations. Assessment of indoor
and outdoor PM2.5 levels in some of the HRV
studies also indicated somewhat greater effects
associated with indoor concentrations (517,518).
Biomarkers of oxidative stress in blood were
associated with personal exposure to PM2.5 and
black smoke but not with ambient background
concentrations (504).
These studies do not clarify whether indoor
or outdoor sources are most relevant to the
observed health effects. In recent studies,
different modeling approaches have been used
to determine ambient and nonambient expo-
sures to then correlate them with observed
health effects (526). In one of these studies
(526), personal PM2.5 exposure was found to be
composed mostly of nonambient particle expo-
sure, and neither total personal nor nonambient
exposure was associated with any of the inves-
tigated health outcomes, with the exception of
an unexpected increase in FEV1. Ambient expo-
sures (as determined from ambient concentra-
tions and time-activity data) were associated
with decreased FEV1 and systolic blood pres-
sure and increased heart rate and supraventricu-
lar ectopic heartbeats. In most cases, ambient
exposures provided better effect estimates than
ambient concentrations. In another study, in-
creases in exhaled NO were more strongly
associated with the ambient-generated compo-
nent of personal exposure (477). Conversely,
and also differing from the previously dis-
cussed results (526), indoor-generated PM2.5
were associated with FEV1 and FVC but not
midexpiratory flow (477). Note that this asso-
ciation was somewhat dependent on the model
used for estimating the indoor-generated com-
ponent of PM2.5 exposure. Interestingly, lag 0
indoor home PM2.5 and PM10 concentrations
CRIAI_31_Final Appl 7/17/06, 1:48 PM65
66 Borchers et al.
Clinical Reviews in Allergy & Immunology Volume 31, 2006
were significantly associated with decreases in
FEV1, whereas residential outdoor and central
site measurements showed some significant
associations with FEV1 only at longer averag-
ing periods in another panel of children with
asthma (463). This also suggests that indoor
and outdoor particles differ in the mechanisms
through which they induce adverse effects on
respiratory health. Although somewhat pre-
liminary in nature, these results suggest that
ambient and nonambient particles are differ-
entially associated with various health out-
comes.
Biologicals
Microbes
The first report of a cluster of people in the
same building becoming ill at the same time
occurred in 1976, when 182 attendees of a con-
vention of the American Legion in Philadel-
phia developed a disease characterized by
respiratory symptoms that proved fatal in 29
of the cases. The disease was named Legion-
naires’ disease, and the organism responsible
was eventually called Legionella pneumonia.
Legionella species are found naturally in warm
and humid environments. In buildings, they
grow in air conditioning cooling towers, hot
water tanks, other parts of the plumbing sys-
tems, and hot tubs. The disease is contracted
by the inhalation of aerosolized droplets of
water that are contaminated with the bacteria,
but it is not spread by person-to-person con-
tact. The incubation period is 2 to 14 d. Every
year, 8000 to 10,000 people are hospitalized
with Legionnaires’ disease. Individuals over
age 65 yr, those with chronic lung diseases,
those who are immunosuppressed, and patients
with chronic illness (such as diabetes or cancer)
are more susceptible. The mortality rate ranges
from 5 to 30%. A less severe, nonrespiratory form
of Legionnaires’ disease was named Pontiac
fever because it was first described in 144
health department facility workers in Pontiac,
Michigan (540). The illness is caused by a bac-
terium with characteristics similar to that of
L. pneumonia; it is self-limiting, and the symp-
toms include headache, fever, malaise, and
myalgias.
Although the etiology of these disease out-
breaks associated with specific buildings was
initially unknown, causative agents were even-
tually identified, making Legionnaires’ disease
and Pontiac fever examples of specific build-
ing-related illnesses. Other microbial agents
have also been reported to cause outbreaks of
disease that are confined to a particular build-
ing. Examples include influenza virus infec-
tions in nursing homes (541–544) and, more
recently, clusters of severe acute respiratory
syndrome cases in a hospital (545) and an
apartment complex (546). However, in these
cases, the buildings were not reservoirs of the
infectious agents. Rather, transmission from
human to human within the building caused
the outbreaks.
Fungi and Molds
Fungi are ubiquitous. They require mois-
ture for growth and survival but can grow on
various substrates, including dead or living
plant and animal tissue, paint, paper products,
and building materials. During reproduction,
they become airborne as mold spores. Fungal
spore concentrations in indoor environments are
measured in either air or dust, and the results are
reported either as viable (culturable) spore con-
centrations in colony-forming units (CFU) per
cubic meter or per gram of dust or as total
(viable and nonviable) spore counts expressed
in spores per cubic meter. The total spore count
can be up to two orders of magnitude higher
than the number of viable microbes.
Viable fungal spore concentrations in more
than 12,000 samples from more than 1700 build-
ings in the United States ranged from below the
detection limit to more than 8200 CFU/m3 in
outdoor air and to more than 10,000 CFU/m3
in indoor air samples (547). Median indoor and
outdoor concentrations were 80 and approx
500 CFU/m3, respectively. Similarly, in 19
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studies from North America, Europe, Asia,
and Australia, total viable spore counts var-
ied between below the detection limit and
23,000 CFU/m3 in indoor air samples from
buildings with visible mold growth (548). With
one notable exception (450,000 CFU/m3), the
maxima in indoor air samples from buildings
without signs of mold growth were lower.
There is seasonal as well as regional variability
in the number of airborne mold spores and in
the ratio of outdoor to indoor concentrations
(547,548). This applies not only to concentra-
tions of total fungi but also to specific genera
and species (549). Outdoor viable as well as
total spore counts are generally higher than,
but show a positive correlation with, indoor
levels (548,549). Indoor mold spore concentra-
tions can exceed those found outdoors in build-
ings with obvious water damage or signs of
mold growth; however, several studies have
reported similar mold spore counts in build-
ings with and without dampness and mold
problems (548,550). The profile of indoor fungi
also differs from that found outdoors, and the
diversity of fungal species is frequently greater
in damp buildings (551).
Worldwide, the most common genera in
indoor and outdoor air are Penicillium, Cla-
dosporium, and Aspergillus (547–549). Species that
require high water activity, such as Stachybotrys
and Trichoderma, are reported much less fre-
quently because of their more infrequent occur-
rence and because they are difficult to culture
with the standard culture methods (547).
(Table 18 provides a list of common airborne
spores and their characteristics.)
Fungal spore release is irregular and de-
pends on various environmental conditions.
Additionally, fungal spores in settled dust can
be resuspended by human activities. Conse-
quently, there can be substantial temporal
variation in airborne spore counts. Measure-
ments of airborne fungal spores fail to capture
this variability and poorly reflect actual expo-
sure because they are usually based on very
short sampling periods (10–30 min). There are
few reports of longer term (24-h) measure-
ments (549,552). In one study, personal expo-
sure of 81 Finnish schoolteachers to total as
well as viable microbes was determined by 24-
h sampling with a personal button particle
sampler and was compared with residential
and workplace indoor concentrations (552).
Geometric mean concentrations of total fungi
were higher in the work environment (9000
spores/m3) than in the home environment
(4700 spores/m3), and concentrations of fungi
in the home environment were similar to per-
sonal exposure levels (5700 spores/m3). The
geometric mean concentrations of viable fungi
were 2 to 3, 5 to 6, and 12 CFU/m3 in work,
home, and personal samples, respectively.
Fungal spores settle with floor dust, which
can be resuspended during walking and other
human activities; therefore, fungal concentra-
tions in floor dust are believed to be a surro-
gate for cumulative exposure. More recently,
fungal components such as extracellular poly-
saccharides (EPS), β-(13)-D-glucans, and er-
gosterol have been measured in house dust
(553,554) and air (555). The results suggest that
they may represent acceptable markers of fun-
gal exposure. Statistically significant, although
not very strong, correlations were detected be-
tween EPS of Aspergillus/Penicillium (EPS-Asp/
Pen) and β-glucan levels in house dust and to-
tal culturable fungi (553,554). The weakness of
the association may reflect that both markers
represent total fungal biomass rather than only
culturable species. In one of the studies, EPS-
Asp/Pen levels in floor dust were found to cor-
relate positively with occupant-reported, but
not investigator-observed, mold and damp-
ness problems in the living room (554). For
bedrooms, the association was inverted, possi-
bly because of allergen avoidance measures. In
110 homes in Canada, airborne β-glucan and
ergosterol concentrations obtained via long-
term active sampling (5–7 d) were highly cor-
related not only with each other but also with
area covered by visible mold growth (as care-
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fully documented by trained inspectors) (555).
The correlation between glucans and total
spore counts was markedly weaker, although
highly significant.
Safe vs Hazardous Mold Levels
There is no consensus regarding what con-
stitutes safe or hazardous levels of mold. How-
ever, there is clearly an enormous variation in
mold levels between cities, depending on their
temperature and humidity. It should also be
obvious that mold has been in the air and in
the environment since long before people ex-
isted. The mere presence of mold even at el-
evated counts does not imply disease, despite
an enormous hype in the media over the so-
called mold-related syndromes. Indeed, cer-
tain environments, such as greenhouses or
situations following floods, have consistently
failed to disclose an epidemic or any disease
cluster. The only exception to this is exacerba-
tion of asthma in individuals who have IgE
directed against mold allergens. The National
Allergy Bureau of the American Academy of
Allergy, Asthma and Immunology interprets
outdoor fungal levels (in counts per cubic
meter) as follows: 0 = absent, 1 to 6499 = low,
6500 to 12,999 = medium, 13,000 to 49,999 =
high, and 50,000 or greater = very high. The
American Academy of Allergy, Asthma and
Immunology also certifies and reports mold
spore data from nearly 80 certified pollen
and mold spore counting centers throughout
the United States and Canada. The measures
that constitute a safe indoor mold spore level
are even less well-defined. Several states and
Table 18
Fungi in Air: Common Airborne Spores
Size of spores
Genus (µ) Substrates and other characteristics
Alternaria 8–75 Multicell, multiseptate spores; grows on plant material and rotting
vegetation, found indoors in damp areas.
Aspergillus 2–10 Stored cereal grains, dead vegetation, found indoors, found outdoors
in compost heaps; spores look similar to Penicillium; speciation can
be done by culture.
Curvularia 18–43 Light brown mold with distinct septae.
Dreschlera Plant debris, soil.
Epicoccum 20 Dark to golden brown; multiseptate spores.
Fusarium Soils, saprophytic on plants, important producer of trichothecenes.
Cladosporium 4–20 Dead vegetation, textiles.
Acremonium Dead organic debris, foodstuffs, soils; small one-cell colorless spores.
Stachybotrys Soils, decaying leaf litter, cellulose, seeds, and decaying plant
substrates.
Trichoderma 2–10 Soils, decaying wood, grains, citrus, damp wood, paper, textiles.
Penicillium 3–5 Used in the manufacture of blue cheese, common indoors, grows on
stored foods, fruit, cheeses, bread.
Periconia 16–18 Soil, grasses, dead leaves, rarely found indoors.
Cephalosporium
Rhizopus Found on spoiling food, decaying fruits, and vegetables.
Mucor Found on organic matter, dung, and soils. Colorless spores.
Stemphyllium 23–75 Saprophytic, grows on cellusic material, including livestock feed,
ceiling tiles, paper, and cotton cloth. It is a diurnal sporulator.
Ulocladium Soil, dung, decaying plant matter, fibers, wood, grasses, textiles, and
paper; may be confused with Alternaria.
Botrytis Teardrop shape spores, saprophytic and parasitic; part of the
Dreschlera group.
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countries have attempted to set standards for
hazardous indoor mold levels. A consensus
has proved elusive, and these standards are not
supported by clinical data or other scientific
evidence. The New York City Department of
Health recommends evacuation if the indoor/
outdoor ratio is greater than 1 and if indoor
concentrations exceed 1000 spores/m3. Brazil
sets the threshold for hazardous exposure at
750 spores/m3, whereas the standard in the
Netherlands is 104 spores/m3 (http://www.
inspect-ny.com/sickhouse/moldlevels.htm).
Ironically, these recommendations were not
developed by vigorous scientific panels: they
were arbitrary. In fact, mold counts higher than
this value are normally found outdoors!
Biomonitoring
There are currently no generally accepted
biomarkers of fungal exposure. Although el-
evated fungal-specific IgG and IgA concentra-
tions have been reported with higher frequency
in an exposed population compared with a
control population (556), researchers have not
distinguished between the two groups. Other
investigators failed to detect significant differ-
ences in the prevalence of IgG antibodies
against S. chartarum between a group of sub-
jects with confirmed exposure to high concen-
tration of this fungus and a control group
(557,558). In our own experience, and that of
others, the use of IgG antibodies has no clinical
value in the so-called mold-related illnesses.
The only important and unusual exceptions to
this are the well-described precipitating IgG
antibodies in hypersensitivity pneumonitis.
Health Effects
Reviews performed by a committee of Eu-
ropean scientists regarding the literature on
health effects associated with building damp-
ness have concluded that dampness in non-
industrial work and residential environments
is associated with a variety of health effects
(559,560). Such health effects (67,109,561–563)
include increased prevalence of self-reported
and physician-diagnosed asthma, decreased
lung function, increased prevalence and sever-
ity of asthmatic and allergic symptoms, aller-
gic sensitization, and inflammatory markers in
nasal lavage. There is also evidence for associa-
tions with other typical SBS symptoms, although
it is weaker than evidence for respiratory symp-
toms. However, the agents responsible for the
increased risk of health effects associated with
exposure to dampness remain unclear. There
is some evidence that house dust mites are in-
volved but do not fully account for the observed
effects. Additionally, it is possible that organic
chemicals given off by degrading building
materials mediate some of the health effects
associated with building dampness. However,
microbiological agents and/or some of their
products are prime candidates.
There have been numerous reports of sig-
nificant associations of SBS symptoms and
other health effects not only with self-reported
visible mold growth, but also with viable fun-
gal spore counts in air and dust (548). Similarly
to building dampness, the associations are
with respiratory symptoms, lung function, and
asthma prevalence. Inconsistent results were
reported for nasal, throat, eye, skin, and gen-
eral symptoms. Recently, however, significant
and dose-dependent associations were detected
between levels of culturable fungi in floor dust
and mucous membrane and general symptoms
in female—but not in male—teachers from 15
Danish public schools (550). Specifically, the
risk of experiencing difficulties in concentrat-
ing was increased more than 10-fold at the
highest exposure levels. Otherwise, however,
the strongest associations with symptoms were
detected for recent airway infections, hay fever,
psychosocial factors, and current smoking sta-
tus. None of the objective measures of health
effects (lung function parameters, IL-8, and
ECP in nasal lavage) were associated with
mold exposure or symptoms. Subsequently, a
controlled exposure study was conducted
with eight school employees who had shown
increased histamine release to P. chrysogenum
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(564). Short-term exposure to high doses of
P. chrosygenum and Trichoderma harzianum spores
did not result in more mucous membrane or
general symptoms than placebo. However,
exposure to a high concentration of fungal
spores for a short period may not accurately
capture the effects of long-term exposure to
low or moderate doses. One should emphasize
that clinical data have only demonstrated a
value of IgE antibodies against allergens as a
predictor of whether health effects are observed.
Although several studies have claimed that
fungi are involved in sinus disease, such data
do not clearly indicate environmental molds
and suggest that recovered mold in cultures is
primarily secondary to overgrowth from the
use of broad-spectrum antibiotics. Often, such
claims of sinus disease and mold are not even
accompanied by appropriate sinus imaging.
Interestingly, studies of children attend-
ing the same schools indicated that levels of
culturable fungi in floor dust were significantly
associated with symptoms in boys only (565).
Specifically, mold exposure increased the risk
of eye irritation, headache, concentration prob-
lems, and dizziness. Similarly to the adult
population, the strongest associations with
symptoms were observed for factors other than
mold exposure—particularly recent airway
infection, hay fever, and psychosocial factors.
As part of the BASE study funded by the
US EPA, repeated measurements of culturable
fungi in air, floor dust, and chair dust were
obtained over a period of 1 yr in 21 offices in
four office buildings in Boston (566). In addi-
tion to work environment and personal factors,
a group of unidentifiable fungi in chair dust
was significantly associated with nonspecific
symptoms in a multivariate analysis. Fungal
concentrations in chair dust also predicted upper
respiratory symptoms as well as work environ-
ment and personal factors.
Few studies have examined the association
between SBS symptoms and aero-allergens by
measuring exposure directly at the worksta-
tion of each participant rather than at a single
site or a few sites within a building. One such
study found that symptoms of the upper and
lower respiratory system were not associated
with total culturable fungi, but they correlated
significantly with detectable airborne Alterna-
ria and house dust mite concentrations (567).
Notably, Alternaria spore counts were low,
with mean levels of 7 and 6 CFU/m3 in the of-
fices and the HVAC supply systems, respec-
tively.
Results from another study involving 48
schools with a high incidence of SBS symptoms
suggested that Penicillium and Stachybotrys
were the main genera associated with these
symptoms (568). In 20 of these schools, Penicil-
lium levels in areas whose occupants reported
a high frequency of SBS symptoms signifi-
cantly exceeded those of areas with a low fre-
quency of complaints as well as Penicillium
levels from outdoor air samples. In the other
schools, airborne Penicillium concentrations
were not elevated, but heavy to very heavy
growth of either Penicillium and Cladosporium
or Stachybotrys species was found in swab
samples from water-damaged areas. Remedial
actions taken by many of the schools report-
edly resulted in indoor air fungal profiles simi-
lar to those found outdoors and were associated
with a marked decrease in the frequency of
symptom reports. However, a causal relation-
ship could not be established, because signifi-
cant bias was inherent in the methodology
used to evaluate subject complaints and because
other possible causes of the complaints were not
investigated. Interestingly, in another building
with a high frequency of indoor air quality
complaints and visible fungal growth in many
rooms, the outdoor fungal profile changed con-
siderably during a 6-h observation period,
whereas the indoor fungal profile underwent
little alteration (569). Similarly to the study of
school buildings, Penicillium was the dominant
species in indoor air at all time-points, whereas
it was the dominant species in outdoor air in
only two of the six samples.
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Other studies have confirmed that remedial
action can result in a significant decrease in the
total airborne viable mold concentration and a
decrease in the microbial diversity along with
a decrease in most of the symptoms assessed
(570). Notably, the concentration of airborne
bacteria also declined after the repair of mois-
ture damage, making it difficult to determine
whether bacterial or fungal exposure were
mainly responsible for the observed symptoms.
Similarly, renovation plus thorough cleaning of
buildings containing a public swimming pool
resulted in a marked decrease in the number of
viable molds, led to a change in the species
composition of the molds, and was associated
with a decrease in the symptom frequency
from 66% before the renovation to 4% after
completion of the intervention (571). However,
as emphasized earlier, these data are con-
founded by discrimination bias and the lack of
controls and often include issues of secondary
gain.
Numerous studies, including several longi-
tudinal studies, have addressed the association
between residential dampness and/or mold
and wheezing and persistent cough in infants
and small children. Although wheezing in in-
fancy does not necessarily develop into asthma
later in life, it is an acknowledged risk factor.
In a case–control study of 251 pairs of small
children, those who were diagnosed with bron-
chial obstruction were significantly more likely
to live in homes with dampness problems in
the 2 yr preceding (as confirmed by indepen-
dent trained investigators or professional build-
ers) (572). In a prospective birth cohort study
of more than 4000 children from Stockholm,
Sweden, home dampness was significantly
associated with the occurrence of asthma or
recurrent wheeze in children followed for the
first 2 yr of their lives (573). Mold odor reported
at baseline, but not water damage or presence
of visible molds, predicted asthma incidence in
a 6-yr prospective cohort study involving chil-
dren age 1 to 6 yr at baseline (574). This asso-
ciation remained significant after adjusting for
parental atopy and various other known risk
factors for the development of asthma, although
there was no adjustment for the presence of
specific allergens.
In infants at high risk of developing asthma
(i.e., those with a mother and an older sibling
with physician-diagnosed asthma), there was a
significant association between frequent wheez-
ing and persistent cough and mothers’ reports
of visible signs of molds and mildew (575). The
number of airborne viable mold spores was
also significantly associated with wheeze, even
after adjusting for several common aero-aller-
gens, environmental exposures, and other
known risk factors.
The same outcomes were assessed in another
study involving 880 infants of mothers who had
at least one older child with physician-diag-
nosed asthma (576). In this study, airborne lev-
els of fungi were categorized into undetectable,
low (1–499 CFU/m3), medium (500–999 CFU/
m3), or high levels (1000 CFU/m3). Infants
exposed to high Penicillium concentrations
were at significantly increased risk of develop-
ing wheeze and persistent cough during their
first year of life. Although the level of Cla-
dosporium spores in indoor air correlated with
occupant-reported mold and water leaks, Cla-
dosporium concentrations were not significantly
associated with either of these symptoms,
whereas reported mold was associated with
persistent cough.
A prospective study of a birth cohort involv-
ing 499 children of atopic parents demonstrated
that those who were exposed to high levels of
certain fungal spores had a higher incidence of
developing lower respiratory tract illnesses
(including bronchiolitis, croup, pneumonia,
and bronchitis) in the first year of life (577). Spe-
cifically, significant associations were detected
between lower respiratory tract illness and air-
borne (but not dust-borne) Penicillium and
dust-borne (but not airborne) Cladosporium,
Zygomycetes, and Alternaria. Notably, these
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associations were observed after controlling
for markers of moisture damage, which inde-
pendently predicted lower respiratory tract ill-
ness. In all three studies that measured fungal
concentrations (575–577), exposure to mold
was assessed on only one occasion early in each
infant’s life, few other environmental expo-
sures were accounted for, and only one inves-
tigation examined the simultaneous effects of
molds and other aero-allergens (particularly
house dust mites, cats, dogs, and cockroaches)
(575). Therefore, substantial misclassification
of fungal exposure cannot be ruled out, and a
causal relationship cannot be definitively estab-
lished.
Results of time series studies have indi-
cated that increased concentrations of outdoor
fungal spores are associated with decreases in
PEFR in unselected children (578) and in chil-
dren with asthma (459,579) and with increases
in asthma symptom severity and inhaler use
(459, 580) and in the number of emergency
hospital visits for asthma in children (581);
however, this association was not observed
in another study (582). Fungal spore levels
have also been reported to be associated with
increased mortality from asthma in persons
ages 5 to 34 yr (583).
Mechanisms
The mechanisms by which exposure to air-
borne fungi may induce SBS symptoms and
related health effects appear secondary to IgE-
mediated disease. Sensitization to fungal aller-
gens has been reported to be significantly
associated with asthma, although considerable
regional variation in the rates of sensitization
was noted (584). For example, among children
with bronchial hyperreactivity, 56% had elevated
IgE antibodies (CAP scores 2) against Alter-
naria allergens in Los Alamos, New Mexico,
compared with only 19% in Albemarle, Vir-
ginia (584). Control patients had a significantly
lower prevalence of scores greater than 2. The
overall sensitization rate was 20% for Alterna-
ria allergens compared with only 8% to Cla-
dosporium allergens. Similarly, rates of sensiti-
zation to Cladosproium in more than 11,200 sub-
jects from various European countries ranged
between 1 and 7% (585). Sensitization to Cla-
dosporium was associated with increased bron-
chial hyperresponsiveness to metacholine in
some countries, but there was no association in
other countries or in the group overall. Addi-
tionally, spore extracts of Basidiomycetes, Cla-
dosporium, and Penicillium can induce early and
late asthmatic reactions in sensitized subjects
(586,587).
β-(13)-D-glucans are glucose polymers
that are cell wall components of most fungi and
of some bacteria and many plants. A large
variety of β-(1 3)-D-glucans exists, with
varying molecular weights, solubility charac-
teristics, conformations (triple helix, single helix,
random coil), and degrees of branching (fre-
quency of attachment of β-[16]-glucan side
branches). Each one of these characteristics
affects the type and extent of biological activity,
which is predominantly immunostimulatory.
The number of different β-glucans that have
been investigated in experimental studies is
very limited. β-(13)-D-glucans have been used
as markers of fungal exposure, but it remains
unclear to what extent they contribute to the
health effects attributed to such exposure. One
researcher recently reviewed epidemiological
and controlled exposure studies along with
data from animal experiments investigating
the effects of fungal β-glucans on respiratory
health (588). The author concluded that the
epidemiological data suggested an association
between β-glucan exposure and airway inflam-
mation and respiratory symptoms. However,
the available evidence was inconsistent and
suffered from insufficient statistical power,
lack of control for other potential causal agents,
and potentially from considerable exposure
misclassification. The results of animal studies
suggest that high concentrations of β-glucans
have the potential to induce airway inflamma-
tion and to enhance specific IgE sensitization,
although neither were consistent findings.
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Notably, extracts of Cladosporium herbarum and
P. chrysogenum, both molds that colonize damp
building walls, were reported to enhanced
OVA-specific IgE and IgG1 response in mice
when administered subcutaneously (589).
The β-glucan concentrations of the extracts
were very low, suggesting that other fungal
components were primarily responsible for
this adjuvant effect.
Certain molds are able to produce toxic
metabolites known as mycotoxins. They have
been studied most extensively in the context of
fungal contaminants of foods such as wheat,
grapes, rice, maize, oilseeds, and so forth. The
fungi that contaminate these grains and foods
are also common household fungi, and it is
believed that humans can be exposed to myc-
otoxins in indoor air. Examples of fungi that can
produce mycotoxins include Fusarium, Aspergil-
lus, Alternaria, Penicillium, and Stachybotrys.
The most common mycotoxins belong to a
class of molecules called trichothecenes (ref.
590; see Table 19 for the various categories of
mycotoxins and the types of trichothecenes).
Trichothecenes are a group of structurally
similar sesquiterpene molecules, characterized
by a 12, 13-epoxytrichothec-9-ene ring system.
Trichothecenes generally are extremely stable
and are degraded only by heating at high tem-
peratures for a prolonged period. Metabolites
of trichothecenes may be less toxic than the
parent compound (591). Interestingly, how-
ever, mycotoxins do not appear to be airborne,
and even in contaminated air environments,
the quantities that humans are exposed to are
extraordinarily small and require an enormous
exposure for a clinical effect. Therefore, again,
the presence of molds containing mycotoxins
on a wall or on a carpet should not be inter-
preted as indicative of ill health any more than
the likely presence of such mold on the soles of
shoes should be interpreted in the same man-
ner.
The main focus of research on the toxic ef-
fects of mycotoxins in experimental animals
has been on their ingestion as part of the diet.
Such studies have shown that several different
mycotoxins can induce decreased feed effi-
ciency and anorexia (592–594), various effects
on the immune system (predominantly immu-
nosuppression; refs. 592,595, and 596), carcino-
genicity (597,598), and nephrotoxicity. Major
mechanisms of toxicity include the inhibition
of protein synthesis, mitochondrial toxicity,
cytotoxicity, and the induction of apoptosis
(599–601).
Animal studies also indicate that intratra-
cheal instillation of mycotoxin-producing
fungi—particularly Stachybotris chartarum—
can induce considerable pulmonary inflamma-
tion in rats and mice (602,603). Some of these
studies have suggested that the inflammatory
response is mediated mainly by trichothecenes.
However, more recent investigations have pro-
vided evidence that other fungal components
also contribute to the lung pathology induced
by exposure to S. chartarum. Repeated intrana-
sal instillation of S. chartarum spores was found
to cause an influx of monocytes, neutrophils,
and lymphocytes into BALF and to increase
mRNA expression of pro-inflammatory cyto-
kines (IL-1β, IL-6, and TNF-α) and several
chemokines (604). These effects were only
observed at the higher dose (1 × 105 spores per
instillation) and not at the lower dose (1 × 103
Table 19
Mycotoxins
Aflatoxins
Zearalenone
Secalonic D
Trichothecenes
Satratoxins
Trichoverols
Verrucarol
Verrucarins
Trichoverrins
T-2 toxin
Nivalenol
Deoxynivalenol
Diaceroxyserpenol
Isosatratoxin F
Ochratoxin A
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spores per instillation). Neither T-helper 1 or
T-helper 2 cytokines nor total or specific IgE,
IgG1, and IgG2a levels were significantly in-
creased by S. chartarum instillation. Notably, a
strain of S. chartarum that produced satratoxin
and a strain that did not produce satratoxin
were used in the experiments. The inflamma-
tory effects of the two strains were almost iden-
tical, indicating that satratoxin was not required
for the induction of pulmonary inflammation.
Similar results were reported from an inves-
tigation of the effects of intratracheal adminis-
tration of 1 × 105 intact, autoclaved, and
ethanol-extracted spores of S. chartarum in 7-d-
old rats (605). During the 72 h following expo-
sure to all three types of fungal spores, there
was a significant reduction in alveolar space
with simultaneous elevation of TNF-α, IL-1β,
and neutrophils in BALF. Intact spores had the
greatest effect, followed by autoclaved and
ethanol-extracted spores. Differences in the
time-course of the response indicated that the
trichothecenes were the main contributors to
the early inflammation, which peaked 24 h
after exposure, although proteins already par-
ticipated. Peak release of proteins and/or other
fungal compounds occurred later in the inflam-
matory response and appeared to be mainly
responsible for prolonging it.
In another study, mice received intratrachel
instillations of 30, 300, or 3000 spores/g body
weight (or 7500–750,000 spores per instillation)
of a trichothecene- or atranone-producing strain
of S. chartarum or of Cladosporium cladosporioides
(606). Both of the S. chartarum strains, but not
C. cladosporioides, caused marked vascular leak-
age in the lung, although they had very differ-
ent time-courses. Significant increases in BALF
TNF-α concentrations were noted after treat-
ment with all three fungi but did not show a linear
dose–response in the case of the two S. chartarum
strains. Conversely, IL-6 levels in BALF rose
with increasing spore dose, with only the high-
est dose of all three fungi producing statisti-
cally significant increases. Only the highest
dose of the atranone-producing S. chartarum
strain significantly raised IL-1β concentrations.
However, note that the lowest dose of the other
strain induced similar levels, but they were not
statistically significantly different from con-
trols. Together, these results clearly suggest
that substances other than trichothenes and
atranones contributed to lung inflammation
and pathology. This confirms the findings of
the other studies, which also indicate that myco-
toxins play an important role in lung inflamma-
tion and pathology but do not support the
hypothesis that mycotoxins are solely respon-
sible for these effects. Note that these results
cannot be directly translated to humans because
they were obtained with very high doses of
spores corresponding to between 21 million  to
more than 1 billion spores for an average 70-kg
human.
The potential health effects of exposure to
Stachybotrys and its associated mycotoxins
(satratoxins) were examined in 53 occupants of
a water-damaged building (557). There was an
association detected between the presence of
satratoxin H and spirocyclic lactones and lower
respiratory, dermatological, eye, constitutional,
and chronic fatigue symptoms. Additionally,
occupants of the water-damaged building exhib-
ited a lower proportion of mature T-lympho-
cytes compared with controls without any
contact to the test site. This was not a double-
blind study, and there was no effort to rule out
other causes of the occupants’ symptoms. There-
fore, no conclusion can be made from this study
regarding a causal effect of trichothecenes on
human health.
Specific Sinopulmonary Diseases Caused
by Mold and Other Microbial Agents
Aspergillus fumigatus and related species
have been found to play a role in numerous
pulmonary and upper airway diseases. These
diseases include allergic bronchopulmonary
aspergillosis (ABPA), allergic fungal sinusitis,
and hypersensitivity pneumonitis.
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ABPA is an allergic reaction to a fungus
that mimics pneumonia; it is characterized
clinically by asthma and airway inflammation
and serologically by increased titers of Aspergil-
lus-specific IgE in the blood. Increased eosino-
phils are present in lung tissue. The usual
culprit is A. fumigatus, a fungus that grows in
soil, decaying vegetation, food, water, and/
or dust. Other fungi, including Penicillium,
Helminthosporium, Curvularia, and Candida,
may cause a similar disease. Sensitization to the
fungus leads to an inflammatory response in the
lungs and airways, which includes eosinophil
infiltration and increased mucus production.
Eventually, bronchiectasis and pulmonary fibro-
sis can occur. Symptoms include wheezing,
shortness of breath, cough productive of brown-
ish mucus, fever, and malaise. Changes observed
in chest radiographs are consistent with pneu-
monia. Laboratory studies have revealed high
levels of Aspergillus-specific IgE and elevated
peripheral blood eosinophils. Aspergillus skin
testing reveals sensitization, but the test is also
positive in patients with a simple allergy to
Aspergillus. Treatment for ABPA includes cor-
ticosteroids and antifungal agents.
Allergic fungal sinusitis (AFS) is a disease
that is pathologically similar to ABPA, but the
sites of inflammation are the paranasal sinuses.
Other features include nasal polyposis, nasal
and sinus accumulation of fungal debris and
allergic mucin, and crust formation (607). Cul-
tures from the sinuses yield Aspergillus, although
this is not pathognomonic, nor is the lack of posi-
tive Aspergillus cultures enough to rule out
AFS. It is estimated that approx 5% of all patients
with chronic rhinosinusitis have AFS. It is more
common in atopic patients who have a diagno-
sis of allergic rhinitis and who test positive to
one or more fungal allergens. AFS primarily
affects young adults, and most cases are geo-
graphically distributed in temperate areas with
high humidity. Aside from Aspergillus, AFS
can be caused by dematiaceous fungi, includ-
ing Bipolaris, Curvularia, Exserohilum, Drechslera,
Alternaria, Helminthosporium, and Fusarium.
There is controversy regarding whether AFS is
an infectious or allergic disease. The fact that
most patients with AFS have positive skin test
and radioallergosorbent test to fungal aller-
gens, as well as the prominent incidence of
atopy in patients with AFS, support an allergic
component to this disease. Eosinophils also
play a significant role in AFS, and ECP levels
were significantly higher in the mucin of patients
with AFS compared with control patients
(608). Criteria for diagnosis of AFS include
radiographical evidence of sinusitis, positive
fungal stain or culture from the sinus at time of
surgery, presence of allergic mucin, absence of
fungal invasion, and absence of contributory
factors such as immunodeficiencies or diabe-
tes mellitus (609). Differential diagnoses of AFS
include saprophytic fungal growth, fungus
balls of the sinuses, eosinophilic mucin sinusi-
tis, and invasive fungal sinusitis. Hypersen-
sitivity pneumonitis is another respiratory
disease that is probably caused by microbes,
but it is primarily an allergic disease. Hyper-
sensitivity pneumonitis frequently occurs as
occupational asthma, and several etiological
agents have been cited. Examples of hyper-
sensitivity pneumonitis and their suspected
source include Farmer’s lung (moldy hay), bird
fancier’s lung (parakeet droppings), pigeon
breeder’s disease (pigeon droppings), hen
worker’s lung (chicken droppings), bagasso-
sis (sugar cane), mushroom worker’s lung
(mushroom compost), air conditioner lung
(contaminated humidifiers or air conditioners),
cork worker’s lung (mold cork), malt worker’s
lung (moldy malt or barley), sequoiosis (moldy
bark from redwoods), and woodworker’s lung
(wood dust). Symptoms include fever, chills,
cough, and respiratory distress occurring 4 to
8 h after re-exposure to the inciting agent. If
prolonged exposure is present, then the dis-
ease progresses into a chronic form and fibro-
sis develops, eventually leading to respiratory
failure. Diagnosis is primarily based on clini-
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cal features, but it is supported by identifica-
tion of the source agent, presence of specific
antibodies in blood, chest radiography, pul-
monary function tests, and lung biopsy. Treat-
ment is based on avoidance and the use of
corticosteroids. Therefore, it is important that
individual patients be examined, including
vigorous review of medical histories, physical
examinations, and appropriate diagnostic
testing to confirm and establish diagnosis and
begin appropriate therapy.
Discussion and Conclusions
We are continuously exposed to a wide vari-
ety of environmental pollutants, and many of
them individually have been shown to have
detrimental effects on health and development
in experimental animals. Fewer studies exist
for humans, and the results are not always
consistent. This is not unexpected, however,
because almost all current research neglects
that humans are exposed to a myriad of envi-
ronmental pollutants and that interactions
between compounds may be responsible for
the various symptoms and diseases that have
reportedly increased in incidence in recent
decades.
Certain VOCs, formaldehyde, phthalates,
and possibly OPs and carbamate pesticides
have all been linked to lower respiratory symp-
toms in humans. Not only OCs, but also OP
compounds, may induce subtle neurodevel-
opmental defects. Similarly to certain phtha-
lates, the major DDT metabolite, p,p’-DDE, has
been shown to be a potent anti-androgen in
vitro and in vivo (610). Gestational exposure to
p,p’-DDE resulted in reduced anogenital dis-
tance at birth and retention of thoracic nipples
on postnatal day 13, but it did not decrease tes-
tosterone levels. Similarly, exposure to TCDD
and certain PCBs can cause developmental
toxicity that is manifest particularly in the
male reproductive system (276). Conversely,
o,p’-DDT, a minor component of technical
grade DDT, and some DDT metabolites exhibit
estrogenic activity, as do some hydroxylated
PCB metabolites, whereas other PCBs and their
metabolites act as anti-estrogens (276,610–614).
This indicates a substantial potential for inter-
actions among this large variety of compounds.
Associations with decreased semen qual-
ity have been suggested not only for certain
phthalates (145,146) but also for PCBs overall
and/or individual PCB congeners and their
metabolites (293,615,616), p,p’-DDE (293), and
OP pesticides (175,617,618). Results from an
exploratory analysis suggest a greater than
additive interaction between MBzP and MBP
and PCB-153 and CYP450-inducing PCBs (619).
It was proposed that this interaction could result
from the inhibition of UDP-glucuronosyl trans-
ferase by hydroxylated PCBs, which results in
greater amounts of free phthalate monoesters,
believed to be the main biologically active me-
tabolites. Unfortunately, neither OH-PCBs nor
the ratio of free vs glucuronidated phthalate
monoesters was determined.
There have been few attempts to address
the interaction of mixtures of compounds at
physiologically relevant concentrations. A
notable exception is the pioneering work by
Kortenkamp and colleagues. For example,
they showed that a mixture of the OCs, o,p’-
DDT, p,p’-DDT, p,p’-DDE, and β-hexachloro-
cyclohexane exhibited combination effects
on MCF-7 human breast cancer cell prolifera-
tion (E-SCREEN) when each of the components
was used at concentrations at or below their re-
spective no-observed effect concentrations
(620). Similar results were obtained with com-
binations of up to 12 estrogenic chemicals in
the yeast estrogen screen assays (612,621,622).
Generally, the concentration addition model
provided excellent predictions of the observed
effects, whereas the independent action model,
for the most part, did not. However, there were
indications that cytotoxic or growth inhibitory
effects of compounds included in mixtures
might compromise the ability of the model to
predict combination effects (622). The model of
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concentration addition was also found to accu-
rately predict the effects of certain binary mix-
tures of environmental estrogens in vivo, using
juvenile rainbow trout as the animal model and
vitellogin induction as the measured end point
(623).
These findings “put into sharp relief the
limitations of the traditional focus on single
agent effects during hazard and risk assess-
ments” (612), not only of the endocrine-dis-
rupting chemicals this comment referenced but
of many other environmental toxicants.
Organic matter, such as proteins derived
from living organisms, or toxins emitted by liv-
ing organisms can also be associated with respi-
ratory diseases. Combinations of aero-allergens
can result in chronic allergic illnesses, includ-
ing allergic rhinoconjunctivitis, sinusitis, and
asthma. Mycotoxins released from fungi have
not been demonstrated to cause human illness,
although in vitro studies have demonstrated
numerous cellular effects. Further research
needs to be performed to characterize whether
or not clinical effects of mycotoxins exist.
SBS has been described since 1982, but
there are no consistent data showing a common
cause for the myriad of symptoms described. We
do know that the symptoms are nonspecific and
occur in more than one person in the same
building and that multiple agents, as described
earlier, have been cited as etiological factors. In
addition to toxins, chemicals, and bioaerosols,
there may be a major psychological component
to SBS.
We need the concerted effort of scientists
from many different disciplines—particularly
from informatics—for the identification of
biological and nonbiological toxicants and
the unraveling of their contribution to health
effects in humans and wildlife. This should
finally bring the power of computers to bear
on the inordinate complexity of interactions
among environmental pollutants as well as the
interactions between pollutants and the organ-
isms they affect.
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